Search Result
Results for "
Methicillin-Resistant Staphylococcus aureus
" in MedChemExpress (MCE) Product Catalog:
3
Biochemical Assay Reagents
| Cat. No. |
Product Name |
Target |
Research Areas |
Chemical Structure |
-
- HY-A0097
-
|
Antibiotic MDL-507; MDL-507
|
Bacterial
Antibiotic
|
Infection
|
|
Teicoplanin is a glycopeptide antibiotic indicated for use in serious infections caused by Gram-positive bacteria, including Methicillin-resistant Staphylococcus aureus and Enterococcus aureus.Teicoplanin shows antiviral activity for HIV-1, SARS-CoV1 and SARS-CoV2. Teicoplanin sodium shows anti-MRSA activity .
|
-
-
- HY-B1924
-
|
N-Demethylvancomycin monohydrochloride; NVCM monohydrochloride
|
Bacterial
|
Infection
|
|
Norvancomycin hydrochloride is a cell wall synthesis inhibitor targeting peptidoglycan precursors of Gram-positive bacteria and cannot pass the blood-brain barrier. Norvancomycin hydrochloride can competitively bind to peptidoglycan precursors, irreversibly inhibit bacterial cell wall synthesis, and exert antibacterial activity. Norvancomycin hydrochloride is mainly used in the study of Gram-positive bacterial infections, especially infections caused by methicillin-resistant Staphylococcus aureus (MRSA) and methicillin-resistant Staphylococcus epidermidis (MRSE). Norvancomycin hydrochloride can also be incorporated into the bionic calcium phosphate coating of titanium implants to enhance antibacterial activity and inhibit postoperative orthopedic infections .
|
-
-
- HY-A0279
-
|
Pristinamycine
|
Bacterial
Antibiotic
|
Infection
|
|
Pristinamycin, produced by Streptomyces pristinaespiralis, is an orally active streptogramin-like antibiotic consisting of two chemically unrelated components: Pristinamycin I (PI) and Pristinamycin II (PII). Pristinamycin is highly active against many antibiotic-resistant pathogens, particularly Gram-positive bacteria, including Methicillin-resistant Staphylococcus aureus (MRSA), Vancomycin-resistant S. aureus (VRSA) and Enterococcus faecium (VREF) .
|
-
-
- HY-14926
-
|
(S)-(-)-Nadifloxacin; WCK 771
|
Antibiotic
Bacterial
|
Infection
|
|
Levonadifloxacin ((S)-(-)-Nadifloxacin; WCK 771) is a broad-spectrum anti-staphylococcal agent. Levonadifloxacin shows antibacterial activity against Methicillin (HY-121544)-susceptible Staphylococcus aureus (MSSA) and Methicillin-resistant S. aureus (MRSA) strains, with a reduction of which phagocytized in THP-1 monocytes .
|
-
-
- HY-N15451
-
|
|
Pyruvate Kinase
|
Infection
|
|
Deoxytopsentin (compound 5) is a marine bisindole alkaloid and also a MRSA pyruvate kinase inhibitor. Deoxytopsentin exists in sponges. Deoxytopsentin exhibits antibacterial activity against methicillin-resistant Staphylococcus aureus strains in vitro .
|
-
-
- HY-156198
-
|
|
Antibiotic
Bacterial
|
Infection
|
|
Bottromycin A2 is a natural antibiotic. Bottromycin A2 is active against methicillin-resistant Staphylococcus aureus (MRSA) and vancomycin-resistant Enterococci (VRE) .
|
-
-
- HY-122735
-
|
|
Ser/Thr Kinase
Bacterial
|
Infection
|
|
Inh2-B1 is a Ser/Thr protein kinase (STK1) inhibitor. Inh2-B1 specifically inhibits STK1 activity by directly binding to its ATP-binding catalytic domain. Inh2-B1 down-regulates cell wall hydrolase genes and disrupts the biofilm formation of Methicillin-resistant Staphylococcus aureus (MRSA) clearly .
|
-
-
- HY-142124
-
|
|
Antibiotic
Bacterial
|
Infection
|
|
Kalimantacin A is a potent antibiotic. Kalimantacin A shows antibacterial activity against staphylococcus including methicillin-resistant staphylococcus aureus (MRSA) .
|
-
-
- HY-127155
-
|
|
Bacterial
Antibiotic
|
Infection
Cancer
|
|
Kigamicin C is an anti-tumor antibiotic that selectively kills pancreatic cancer PANC-1 cells only in nutrient-poor conditions. Kigamicin C has antimicrobial activity against Gram-positive bacteria including methicillin-resistant Staphylococcus aureus (MRSA) .
|
-
-
- HY-128384
-
|
|
Bacterial
|
Infection
|
|
Benzyldodecyldimethylammonium chloride dihydrate is a quaternary ammonium compound (QAC) and can be used as a biocide to target antibiotic-resistant bacteria, such as methicillin-resistant Staphylococcus aureus (MRSA), multidrug-resistant (MDR) P. aeruginosa et. al. Benzyldodecyldimethylammonium chloride dihydrate, an antimicrobial agent, bacteriostatic or bactericidal properties depending on the concentration.
|
-
-
- HY-178912
-
|
|
Reactive Oxygen Species (ROS)
Bacterial
ClpP
|
Infection
Inflammation/Immunology
|
|
Anti-MRSA agent 39 is an orally active ClpX modulator that binds Staphylococcus aureus caseinolytic protease X (SaClpX) with high affinity (Kd = 3.6 μM). Anti-MRSA agent 39 exerts antibacterial effects through temperature-dependent inhibition of cell division. Anti-MRSA agent 39 elicits profound metabolic dysregulation in methicillin-resistant Staphylococcus aureus (MRSA), manifesting as significantly reduced ATP levels, elevated reactive oxygen species (ROS), and decreased NAD+/NADH ratio, and accelerates bacterial lysis rates in MRSA ATCC 33591. Anti-MRSA agent 39 significantly increases the proportion of MRSA cells in the mitotic phase, and the cells exhibit obvious morphological abnormalities. Anti-MRSA agent 39 can be used for the study of invasive MRSA infections .
|
-
-
- HY-N7010
-
|
|
Cholinesterase (ChE)
Bacterial
|
Infection
|
|
(-)-Corynoxidine is an acetylcholinesterase inhibitor with an IC50 value of 89.0 μM, isolated from the aerial parts of Corydalis speciosa .
(-)-Corynoxidine exhibits antibacterial activities against Staphylococcus aureus and methicillin-resistant S. aureus strains in different degrees .
|
-
-
- HY-124199
-
|
|
Antibiotic
Bacterial
|
Infection
|
|
Cephalochromin is an antibiotic and an inhibitor for bacterial fatty acid synthase (FabI). Cephalochromin inhibits FabI of Staphylococcus aureus and Escherichia coli with IC50 of 1.9 and 1.8 μM. Cephalochromin inhibits gram-positive methicillin-resistant S. aureus (MRSA) and quinolone-resistant S. aureus (QRSA), with MIC of 2-8 µg/mL .
|
-
-
- HY-146458
-
|
|
Bacterial
Cytochrome P450
|
Infection
|
|
Antibacterial agent 102 (compound 32) possesses potent in vitro and in vivo antibacterial activity, with MICs < 0.5 μg/mL in Staphylococcus aureus (S. aureus). Antibacterial agent 102 also moderately inhibits CYP3A4 with an IC50 value of 6.148 μM. Antibacterial agent 102 can reduce Methicillin-resistant Staphylococcus aureus (MRSA) load in thigh infected mice .
|
-
-
- HY-A0097A
-
|
Antibiotic MDL-507 sodium; MDL-507 sodium
|
Antibiotic
HIV
SARS-CoV
|
Infection
|
|
Teicoplanin sodium is a glycopeptide antibiotic indicated for use in serious infections caused by Gram-positive bacteria, including Methicillin-resistant Staphylococcus aureus and Enterococcus aureus.Teicoplanin sodium shows antiviral activity for HIV-1, SARS-CoV1 and SARS-CoV2. Teicoplanin sodium shows anti-MRSA activity .
|
-
-
- HY-175301
-
|
|
Bacterial
Reactive Oxygen Species (ROS)
|
Infection
|
|
TH16 is an antibacterial agent (MIC=2 μg/mL against methicillin-resistant Staphylococcus aureus, MRSA). TH16 disrupts bacterial cytoplasmic membrane integrity, elevating intracellular reactive oxygen species (ROS) levels to induce bacterial death. TH16 is promising for research of bacterial infection .
|
-
-
- HY-135422
-
|
Methylustin
|
Bacterial
Fungal
|
Infection
|
|
Nidulin (Methylustin) is a depsidone isolated from a marine fungus Aspergillus unguis. Nidulin shows antifungal and antibacterial against pathogenetic strains, Pseudomonas aeruginosa, Methicillin-resistant Staphylococcus aureus and Candida albicans with inhibition zones of 9.5 mm, 9.0 mm and 9.0 mm, respectively. Nidulin exhibits potent larvicidality against brine shrimp .
|
-
-
- HY-163073
-
|
|
Bacterial
|
Infection
|
|
Anti-MRSA agent 9 (compound 39) shows antibacterial effects against clinically isolated methicillin-resistant Staphylococcus aureus (MRSA) with MIC values of 1 μg/ml. Anti-MRSA agent 9 also shows anti-MRSA efficacy in vivo .
|
-
-
- HY-161803
-
|
|
Antibiotic
Bacterial
|
Infection
|
|
Anti-MRSA agent 12 (Compound SM-5) is an antibiotic, which exhibits antibacterial activity against Staphylococcus aureus, S. epidermidis and Escherichia coli with MIC of 7.81, 7.81 and 62.5 μM. Anti-MRSA agent 12 inhibits the methicillin-resistant S. aureus (MRSA) through inhibition of biofilm formation .
|
-
-
- HY-N3789
-
|
|
Bacterial
|
Infection
|
|
Dunnianol is a natural sesqui-neoligan with moderate antibacterial activity. Dunnianol inhibits Staphylococcus aureus and methicillin-resistant Staphylococcus aureus (MRSA).
|
-
-
- HY-161823
-
|
|
Bacterial
|
Infection
|
|
Anti-MRSA agent 13 (Compound 9b) is an agent against methicillin-resistant Staphylococcus aureus (MRSA), exhibiting a minimum inhibitory concentration (MIC) of 0.5–2 μg/mL against clinically isolated MRSA strains. Anti-MRSA agent 13 possesses favorable biosafety, plasma tolerance stability, and a low tendency to develop resistance. Anti-MRSA agent 13 disrupts cell walls and membranes, reduces metabolic activity, causes oxidative damage, affects DNA function, and ultimately leads to MRSA death through multi-target synergies .
|
-
-
- HY-N3989
-
|
|
Bacterial
UGT
Interleukin Related
SOD
COX
|
Infection
Inflammation/Immunology
|
|
Haplopine is a substance with anti-inflammatory, antioxidant and photoactivated antibacterial activities. It also acts as an inhibitor of UGT1A7 and a photoactivated restriction endonuclease inhibitor. Haplopine inhibits the mRNA/protein expression of IL-6, TSLP, GM-CSF, G-CSF, IL-4, IL-13 and COX-2, while upregulating the mRNA/protein expression of SOD, CAT and HO-1. Haplopine inhibits the glucuronidation reaction catalyzed by UGT1A7 through competitive hydrophobic binding. Haplopine exerts photoactivated restriction endonuclease inhibitory effects by binding to DNA. Haplopine exhibits photoactivated activity against methicillin-resistant Staphylococcus aureus. Haplopine alleviates symptoms of atopic dermatitis. Haplopine can be used in research related to atopic dermatitis and methicillin-resistant Staphylococcus aureus infections .
|
-
-
- HY-N15435
-
|
|
Bacterial
|
Infection
|
|
Conimine is a steroidal alkaloid, antibacterial agent and potentiator. Conimine is isolated from the seeds of Holarrhena antidysenteriaca Wall.ex A.DC. Conimine exhibits intrinsic antibacterial activity against methicillin-sensitive Staphylococcus aureus and methicillin-resistant Staphylococcus aureus. When combined with Penicillin, Conimine shows synergistic antibacterial effects against methicillin-resistant Staphylococcus aureus; when combined with Vancomycin (HY-B0671), it exerts synergistic antibacterial effects against both methicillin-sensitive and methicillin-resistant Staphylococcus aureus .
|
-
-
- HY-115965
-
|
|
Bacterial
Antibiotic
|
Infection
|
|
VP-4604 is a potent anti-methicillin-resistant Staphylococcus aureus (MRSA) agent. VP-4604 exhibits significant microbial growth inhibition toward Staphylococcus aureus (ATCC 43300) with MIC of 4-8 µg/mL. VP-4604 inhibits the growth of methicillin‐resistant Staphylococcus aureus with growth inhibition >95% .
|
-
-
- HY-115964
-
|
|
Bacterial
Antibiotic
|
Infection
|
|
VP-4556 is a potent anti-methicillin-resistant Staphylococcus aureus (MRSA) agent. VP-4556 exhibits significant microbial growth inhibition toward Staphylococcus aureus (ATCC 43300) with MIC of 8 µg/mL. VP-4556 inhibits the growth of methicillin‐resistant Staphylococcus aureus with growth inhibition >95% .
|
-
-
- HY-N14125
-
|
|
Bacterial
|
Infection
|
|
Chloroquinocin has moderate activity against Gram-positive bacteria, including methicillin-resistant Staphylococcus aureus (MRSA) .
|
-
-
- HY-163716
-
|
|
Bacterial
|
Infection
|
|
Antibacterial agent 222 ((R)-O30 (5)) is a antimicrobial agent that inhibits methicillin-resistant Staphylococcus aureus (MRSA) .
|
-
-
- HY-N8186
-
|
|
Bacterial
|
Infection
|
|
(3R)-7,4’-Dihydrohomoisoflavanone is a natural product with antibacterial activities against S. aureus and methicillin-resistant Staphylococcus aureus (MRSA) .
|
-
-
- HY-N13885
-
|
|
Antibiotic
Bacterial
Parasite
|
Infection
|
|
Amythiamicin A is an antimicrobial antibiotic against Gram-positive bacteria (including methicillin-resistant Staphylococcus aureus (MRSA)) and activity against Plasmodium falciparum .
|
-
-
- HY-N14118
-
|
|
Bacterial
|
Infection
|
|
Chloropolysporin B has strong activity of anti-Gram-positive bacteria, including methicillin-resistant Staphylococcus aureus (MRSA) and enterococcus bacteria .
|
-
-
- HY-N14673
-
|
|
Antibiotic
Bacterial
|
Infection
|
|
Helvecardin A is a glycopeptidtic antibiotic. Helvecardin A has strong activity of anti-aerobic and anaerobic Gram-positive bacteria, including methicillin-resistant Staphylococcus aureus .
|
-
-
- HY-N13881
-
|
|
Antibiotic
Bacterial
Parasite
|
Infection
|
|
Amythiamicin C is an antimicrobial antibiotic against Gram-positive bacteria (including methicillin-resistant Staphylococcus aureus (MRSA)) and activity against Plasmodium falciparum .
|
-
-
- HY-157142
-
|
|
Bacterial
|
Infection
|
|
Antibacterial agent 165 (compound 3), a hydroxyquinoline derivative, is a potent bacterial inhibitor. Antibacterial agent 165 inhibits methicillin-resistant Staphylococcus aureus (MRSA) .
|
-
-
- HY-157141
-
|
|
Bacterial
|
Infection
|
|
Antibacterial agent 163 (compound 1), a hydroxyquinoline derivative, is a potent bacterial inhibitor. Antibacterial agent 163 inhibits methicillin-resistant Staphylococcus aureus (MRSA) .
|
-
-
- HY-N14470
-
|
|
Bacterial
|
Infection
|
|
Kigamicin A shows activity against Gram-positive bacteria including methicillin-resistant Staphylococcus aureus (MRSA) with MICs of 0.025-0.78 μg/mL .
|
-
-
- HY-115965R
-
|
|
Reference Standards
Bacterial
Antibiotic
|
Infection
|
|
VP-4604 (Standard) is the analytical standard of VP-4604. This product is intended for research and analytical applications. VP-4604 is a potent anti-methicillin-resistant Staphylococcus aureus (MRSA) agent. VP-4604 exhibits significant microbial growth inhibition toward Staphylococcus aureus (ATCC 43300) with MIC of 4-8 μg/mL. VP-4604 inhibits the growth of methicillin‐resistant Staphylococcus aureus with growth inhibition >95%[1].
|
-
-
- HY-N14476
-
|
|
Bacterial
|
Infection
|
|
Kigamicin B shows activity against Gram-positive bacteria including methicillin-resistant Staphylococcus aureus (MRSA) with MICs of 0.025-0.78 μg/mL .
|
-
-
- HY-N14675
-
|
|
Antibiotic
Bacterial
|
Infection
|
|
Helvecardin B is a glycopeptidtic antibiotic. Helvecardin B has strong activity of anti-aerobic and anaerobic Gram-positive bacteria, including methicillin-resistant Staphylococcus aureus .
|
-
-
- HY-N14706
-
|
|
Bacterial
|
Infection
|
|
Kibdelin A is resistant to Gram-positive bacteria and has similar effects against Staphylococcus aureus (including methicillin-resistant strains) as Vancomycin (HY-B0671) .
|
-
-
- HY-157482
-
|
|
Bacterial
|
Infection
|
|
EBP-59 is a bacterial inhibitor with antibiofilm activity against Gram-positive bacteria. EBP-59 is effective against Staphylococcus aureus and MRSA (methicillin–resistant staphylococcus aureus). EBP-59 can be used to study bacterial infections .
|
-
-
- HY-N14707
-
|
|
Bacterial
|
Infection
|
|
Kibdelin B is resistant to Gram-positive bacteria and has similar effects against Staphylococcus aureus (including methicillin-resistant strains) as Vancomycin (HY-B0671) .
|
-
-
- HY-N14710
-
|
|
Bacterial
|
Infection
|
|
Kibdelin D is resistant to Gram-positive bacteria and has similar effects against Staphylococcus aureus (including methicillin-resistant strains) as Vancomycin (HY-B0671) .
|
-
-
- HY-116168
-
|
|
Antibiotic
Bacterial
|
Infection
|
|
Aldecalmycin is an antibiotic showing antimicrobial activities against Gram-positive bacteria including methicillin-resistant Staphylococcus aureus (MRSA) with MICs values of 6.25-25 μg/mL .
|
-
-
- HY-170567
-
|
|
Topoisomerase
Bacterial
Antibiotic
|
Infection
|
|
DNA gyrase/Topo IV-IN-1 (Compound 27) is an inhibitor of DNA gyrase and topoisomerase IV, exhibiting antibacterial activity. For Escherichia coli and methicillin-resistant Staphylococcus aureus DNA gyrases, DNA gyrase/Topo IV-IN-1 has an IC50 of 11 and 17 nM respectively, and for topoisomerase IV of Escherichia coli and methicillin-resistant Staphylococcus aureus, the IC50 values are 83 and 21 nM respectively. DNA gyrase/Topo IV-IN-1 can be used for research in the field of anti-infection .
|
-
-
- HY-163906
-
|
|
Bacterial
|
Infection
|
|
Anti-MRSA agent 16 (Compound 4) is an inhibitor of methicillin-resistant Staphylococcus aureus (MRSA). Anti-MRSA agent 16 is effective in combination with oxacillin or meropenem in infected mice .
|
-
-
- HY-N14709
-
|
|
Bacterial
|
Infection
|
|
Kibdelin C2 is resistant to Gram-positive bacteria and has similar effects against Staphylococcus aureus (including methicillin-resistant strains) as Vancomycin (HY-B0671) .
|
-
-
- HY-N14708
-
|
|
Bacterial
|
Infection
|
|
Kibdelin C1 is resistant to Gram-positive bacteria and has similar effects against Staphylococcus aureus (including methicillin-resistant strains) as Vancomycin (HY-B0671) .
|
-
-
- HY-174273
-
|
|
Bacterial
|
Infection
|
|
Antibacterial agent 280 (Compound 7af) is an antibacterial agent targeting methicillin-resistant and vancomycin-resistant Staphylococcus aureus (MRSA, VRSA). Antibacterial agent 280 is promising for research of is promising for research of S. aureus infections .
|
-
-
- HY-122008
-
|
|
Bacterial
|
Infection
|
|
Levonadifloxacin ((S)-(-)-Nadifloxacin; WCK 771) arginine is a broad-spectrum antistaphylococcal agent. Levonadifloxacin arginine has antimicrobial activity against methicillin-susceptible Staphylococcus aureus (MSSA) and methicillin-resistant Staphylococcus aureus and reduces phagocytosis of MRSA and MSSA strains by monocytic THP-1.
|
-
-
- HY-14926B
-
|
(S)-(-)-Nadifloxacin arginine; WCK 771 arginine
|
Bacterial
|
Infection
|
|
Levonadifloxacin ((S)-(-)-Nadifloxacin; WCK 771) arginine is a broad-spectrum antistaphylococcal agent. Levonadifloxacin arginine has antimicrobial activity against methicillin-sensitive Staphylococcus aureus (MSSA) and methicillin-resistant Staphylococcus aureus and reduces phagocytosis of MRSA and MSSA strains by monocytic THP-1 cells .
|
-
- HY-130753
-
|
|
Bacterial
|
Infection
|
|
JM 1397 is an antibacterial agent that exhibits potent antibacterial activity against both methicillin-susceptible and methicillin-resistant Staphylococcus aureus with a minimum inhibitory concentration (MIC90) of 1 μg/mL . .
|
-
- HY-N5195
-
|
Nocathiacine II
|
Bacterial
|
Infection
|
|
Nocathiacin II (Nocathiacine II) is highly resistant to Gram-positive bacteria, including methicillin-resistant Staphylococcus aureus (MRSA), penicillin-resistant Streptococcus pneumoniae (PRSP) and multidrug resistant Enterococcus faecalis (MREF) .
|
-
- HY-118036
-
|
|
Topoisomerase
|
Infection
|
|
ACT-387042 is a bacterial topoisomerase inhibitor with broad-spectrum activity against Gram-positive and Gram-negative bacteria, including methicillin-resistant Staphylococcus aureus and penicillin- and fluoroquinolone-resistant Streptococcus pneumoniae .
|
-
- HY-N5184
-
|
Nocathiacine III
|
Bacterial
|
Infection
|
|
Nocathiacin III (Nocathiacine III) is highly resistant to Gram-positive bacteria, including methicillin-resistant Staphylococcus aureus (MRSA), penicillin-resistant Streptococcus pneumoniae (PRSP) and multidrug resistant Enterococcus faecalis (MREF) .
|
-
- HY-163762
-
|
|
Bacterial
|
Infection
|
|
Antibacterial agent 226 (Compound 7f) is an antibacterial agent, that inhibits Staphylococcus aureus strains and methicillin-resistant S. aureus strain with MIC of 2 μg/mL. Antibacterial agent 226 exhibits cytotoxicity to HEK293 with IC50 of 1.9 μM .
|
-
- HY-175338
-
|
|
Bacterial
|
Infection
|
|
Anti-MRSA agent 34 (Compound 6) is an antimicrobial agent targeting methicillin-resistant Staphylococcus aureus (MRSA) (MIC=14 μg/mL). Anti-MRSA agent 34 is promising for research of microbial infection .
|
-
- HY-162564
-
|
|
Bacterial
|
Infection
|
|
Antibacterial agent 221 (compound 3k) is a potent inhibitor of Gram-positive Methicillin-resistant Staphylococcus aureus (MRSA). Antibacterial agent 221 shows significant cytotoxicity against human LO2 and HepG2 cells .
|
-
- HY-N14899
-
|
|
Bacterial
|
Infection
|
|
Oxasetin has medium activity against Gram-positive bacteria, including Methicillin-resistant Staphylococcus aureus and Vancomycin-resistant Enterococcus faecalis (MIC is 16 μg/mL). Oxasetin has no activity against Gram-negative bacteria and fungi .
|
-
- HY-173080
-
|
|
Bacterial
|
Infection
|
|
Antibacterial agent 267 (Compound h19) is a pleuromutilin derivative with a potent antibacterial activity on Gram-positive bacteria. Antibacterial agent 267 shows an antibacterial activity in methicillin-resistant Staphylococcus aureus (MRSA)-infected mouse models .
|
-
- HY-W112166A
-
|
|
Bacterial
|
Infection
|
|
4,4'-Dicyanostilbene (compound 43) is a potent antimalarial agent against the Dd2 strain, with an EC50 of 27 nM. 4,4'-Dicyanostilbene exhibits in vivo efficacy against methicillin-resistant Staphylococcus aureus (MRSA) .
|
-
- HY-108021
-
|
|
Bacterial
|
Infection
|
|
HT-61 is a quinolone antibacterial agent. HT-61 exhibits bactericidal activity against gram-positive bacteria including methicillin-susceptible Staphylococcus aureus (MSSA) and methicillin-resistant Staphylococcus aureus (MRSA). HT-61 can enhance the effect of Tobramycin (HY-B0441) against Pseudomonas aeruginosa .
|
-
- HY-N14955
-
|
|
Antibiotic
Bacterial
|
Infection
|
|
3-O-α-D-Forosaminyl-(+)-griseusin is a memberof naphthoquinone antibiotic. 3-O-α-D-Forosaminyl-(+)-griseusin is active against Gram-positive bacteria including methicillin-resistant strain of Staphylococcus aureus (MRSA) .
|
-
- HY-161018
-
|
|
Bacterial
Antibiotic
|
Infection
|
|
CF3–K11 is a stable antibiotic with antibacterial activity. CF3–K11 has strong antibacterial activity against Pseudomonas aeruginosa and methicillin-resistant Staphylococcus aureus (MRSA).
|
-
- HY-14926A
-
|
(S)-(-)-Nadifloxacin arginine hydrate; WCK-771A arginine hydrate
|
Antibiotic
Bacterial
|
Infection
|
|
Levonadifloxacin (arginine) hydrate is a broad-spectrum anti-staphylococcal agent. Levonadifloxacin (arginine) hydrate shows antibacterial activity against Methicillin (HY-121544)-susceptible Staphylococcus aureus (MSSA) and Methicillin-resistant S. aureus (MRSA) strains, with a reduction of which phagocytized in THP-1 monocytes .
|
-
- HY-146403
-
|
|
Bacterial
|
Infection
|
|
Antibacterial agent 98 (compound g37) is a potent and orally active antibacterial agent. Antibacterial agent 98 inhibits the ATPase activity of Gyrase B and impairs Staphylococcus aureus (S. aureus ) DNA supercoiling. Antibacterial agent 98 shows antibacterial activity and not induce resistance development of MRSA (methicillin-resistant S. aureus) .
|
-
- HY-N15019
-
|
|
Antibiotic
Bacterial
|
Infection
|
|
Glycothiohexide α is a peptide antibiotic. Glycothiohexide α has strong activity against Gram-positive bacteria including methicillin-resistant Staphylococcus aureus (MRSA) and vancomycin resistant enterococcus (VREF), MIC values of 0.03-0.06 μg/mL .
|
-
- HY-N14171
-
|
|
Bacterial
Fungal
|
Infection
|
|
Epicorazine A has activity against Gram-positive bacteria, including methicillin-resistant Staphylococcus aureus (MRSA) and vancomycin resistant enterococcus (VRE), MICs of 12.5-25 μg/mL. Epicorazine A also has effect on Candida albicans with a MIC of 25 μg/mL .
|
-
- HY-173240
-
|
|
Bacterial
|
Infection
|
|
IPMCL-28b is an antibacterial agent targeting the bacterial cell membrane. Its minimum inhibitory concentration (MIC) against Staphylococcus aureus ATCC 25923 is 1.56 μg/mL, and the MIC against methicillin-resistant Staphylococcus aureus (MRSA) is 6.25 μg/mL. IPMCL-28b is expected to be used in the research of the anti-infection field .
|
-
- HY-N19935
-
|
|
Bacterial
|
Infection
|
|
Mammea B/BA is a bacteriostatic agent found in the seeds of Mammea americana L. Mammea B/BA inhibits growth of Staphylococcus aureus strains. Mammea B/BA can be used for the research of methicillin-resistant Staphylococcus aureus infection .
|
-
- HY-146428
-
|
|
Bacterial
|
Infection
|
|
Anti-MRSA agent 4 (compound 7a) is a potent and selective growth inhibitor of Gram-positive Methicillin-resistant Staphylococcus aureus (MRSA), with MIC ≤ 0.26 µM. Anti-MRSA agent 4 exhibits no cytotoxic and no hemolytic activity in HEK293 cells .
|
-
- HY-Z8025
-
|
|
Bacterial
|
Infection
Inflammation/Immunology
|
|
Deprodone is an active compound. Deprodone inhibits key processes such as bacterial cell wall synthesis by interacting with the hydrolase and transferase proteins of methicillin-resistant Staphylococcus aureus (MRSA). Deprodone is used in research on anti-MRSA infection, inflammatory skin disorders, bowel disease, and fatty acid metabolism disorders .
|
-
- HY-174985
-
|
|
Bacterial
|
Infection
|
|
Anti-MRSA agent 32 (Compound 26) is an orally active and selective SaClpP (Staphylococcus aureus ClpP protease) activator with an EC50 value of 0.98 μM. Anti-MRSA agent 32 activates SaClpP to abnormally degrade bacterial proteins, inhibiting the proliferation of Staphylococcus aureus. Anti-MRSA agent 32 promotes wound healing in a murine skin infection model. Anti-MRSA agent 32 is promising for research of infectious diseases such as methicillin-resistant Staphylococcus aureus (MRSA) infections .
|
-
- HY-156289
-
|
|
Bacterial
|
Infection
|
|
Anti-MRSA agent 8 (Compound 7g) is a DAPG derivative with strong antibacterial activity. Anti-MRSA agent 8 assertes its activity by targeting bacterial cell membranes. Anti-MRSA agent 8 can be used for the research of methicillin-resistant Staphylococcus aureus (MRSA) .
|
-
- HY-122174
-
|
CP-5609
|
Antibiotic
Bacterial
|
Infection
|
|
ME-1036 (CP-5609) is a carbapenem antibiotic. ME-1036 against resistant Gram-positive organisms, including Methicillin-resistant Staphylococcus aureus (MRSA), and vancomycin-resistant Enterococci (VRE), and ESBL-producing E. coli and K. pneumoniae but is not effective against P. aeruginosa .
|
-
- HY-141648
-
|
|
Bacterial
|
Infection
|
|
Antibacterial agent 219 (Compound 2/75c) exhibits antibacterial activity by targeting cell wall biosynthesis. Antibacterial agent 219 inhibits methicillin-resistant Staphylococcus aureus (MRSA) strains (MIC=0.5-32 µg/mL), Enterococcus faecium (MIC=2 µg/mL) and S. aureus (MIC=2 µg/mL) .
|
-
- HY-173197
-
|
|
Bacterial
|
Infection
|
|
PBP4-IN-1 (Compound 1) is an inhibitor of penicillin-binding protein 4 (PBP4) of Staphylococcus aureus. PBP4-IN-1 enhances the inhibitory activity of antibiotics against PBP2a-mediated methicillin-resistant Staphylococcus aureus (MRSA) by inhibiting the function of PBP4. PBP4-IN-1 can be used for the study of osteomyelitis caused by Staphylococcus aureus and for the study of reversing PBP4-mediated resistance to β-lactam antibiotics.
|
-
- HY-17626B
-
|
WCK-2349 hydrochloride
|
Antibiotic
|
Infection
|
|
Alalevonadifloxacin (hydrochloride) (WCK-2349 (hydrochloride)) is a oraaly active anti-methicillin-resistant Staphylococcus aureus (MRSA) antibiotic .
|
-
- HY-161893
-
|
|
Bacterial
|
Infection
|
|
Anti-MRSA agent 15 (Compound 9o10) exhibits antibacterial activity, that inhibits methicillin-resistant Staphylococcus aureus (MRSA) with a MIC of 0.0625 μg/mL. Anti-MRSA agent 15 exhibits low hemolysis and low cytotoxicity. Anti-MRSA agent 15 exhibits anti-infective in mice .
|
-
- HY-144822
-
|
|
Bacterial
|
Infection
|
|
Anti-MRSA agent 2 (compound 14) has highly inhibitory activity against Methicillin-resistant Staphylococcus aureus (MRSA) with MIC of 0.098 μg/ml, and relatively low cytotoxicity in normal cells. Anti-MRSA agent 2 has strong ability to destroy bacterial membrane and bind to genomic DNA .
|
-
- HY-N14144
-
|
|
Bacterial
|
Infection
Cancer
|
|
Cremimycin has anti-Gram-positive bacteria activity including methicillin-resistant Staphylococcus aureus (MRSA), MIC is 0.2-0.39 μg/mL. Cremimycin shows cytotoxicity to mouse tumor cell lines P388, L1210, IMC, S180, B16 and SS3 in vitro .
|
-
- HY-155682
-
|
|
Bacterial
|
Infection
|
|
Antibacterial agent 150 (compound 5g) is an antibacterial agent with potent antibacterial activity against both Gram-positive bacteria and Gram-negative bacteria (MIC values ranging from 1-32 μg/mL). Antibacterial agent 150 can increase survival rate of MRSA (Methicillin-resistant Staphylococcus aureus)-infected mice .
|
-
- HY-156122
-
|
|
Dihydrofolate reductase (DHFR)
Bacterial
|
Infection
|
|
DHFR-IN-8 (compound 6r) is a dihydrofolate reductase (DHFR) inhibitor that affects purine and thymidylate biosynthesis in cell proliferation and growth. DHFR-IN-8 inhibits methicillin-resistant Staphylococcus aureus (MRSA) ATCC 43300 (IC50=15.6 ng/mL) in mouse models of systemic infection and thigh infection .
|
-
- HY-W034984
-
|
|
Bacterial
|
Infection
|
|
(1,5-Cyclooctadiene) dimethylplatinum (II) (Compound Pt3) is an Antibacterial agent. (1,5-Cyclooctadiene) dimethylplatinum (II) exhibits limited but selective activity against some Gram-positive Staphylococcus aureus strains, including methicillin-resistant Staphylococcus aureus (MRSA) and Glycopeptide-intermediate Staphylococcus aureus (GISA). (1,5-Cyclooctadiene) dimethylplatinum (II) shows no hemolytic activity .
|
-
- HY-P11622
-
|
|
Drug Derivative
|
Infection
|
|
Gramicidin S analogue 9 is a bactericidal agent that can be found as a cyclic peptide analogue. Gramicidin S analogue 9 disrupts bacterial cell membranes. Gramicidin S analogue 9 can be used for the research of methicillin-resistant staphylococcus aureus infection .
|
-
- HY-181819
-
|
|
Bacterial
Topoisomerase
|
Infection
|
|
Antibacterial agent 327 (Compound 6f) is an Antibacterial agent. Antibacterial agent 327 potently inhibits the supercoiling activity of Staphylococcus aureus DNA gyrase with an IC50 of 0.28 μM. It also inhibits the ATPase activities of DNA gyrase and Topoisomerase IV, as well as the decatenation activity of Topoisomerase IV (IC50: 0.43 μM, 0.73 μM, and 2.31 μM, respectively). Antibacterial agent 327 potently inhibits Clostridioides difficile and methicillin-resistant Staphylococcus aureus (HY-121544), with an MIC of 0.78 μg/mL for both. Antibacterial agent 327 inhibits Escherichia coli with an MIC50 of 0.78 μg/mL .
|
-
- HY-N15249
-
|
Isovalerylspiramycin I; Shengjimycin E
|
Topoisomerase
DNA/RNA Synthesis
Checkpoint Kinase (Chk)
Apoptosis
Bacterial
|
Infection
Cancer
|
|
4"-Isovalerylspiramycin I (Isovalerylspiramycin I) is a topoisomerase 1 (TOP1) inhibitor and an antitumor agent. 4"-Isovalerylspiramycin I directly binds to TOP1, suppresses DNA replication, and induces DNA damage. 4"-Isovalerylspiramycin I downregulates phosphorylated CHEK1 and the ATR/CHEK1 DNA damage repair pathway, blocks DNA repair, and augments DNA damage. 4"-Isovalerylspiramycin I suppresses proliferation, migration, and invasion of osteosarcoma cells. 4"-Isovalerylspiramycin I induces apoptosis and cell cycle arrest in osteosarcoma cells. 4"-Isovalerylspiramycin I exerts antibacterial activity against methicillin-resistant Staphylococcus aureus. 4"-Isovalerylspiramycin I can be used for the research of osteosarcoma, upper respiratory bacterial infections, and methicillin-resistant Staphylococcus aureus infection .
|
-
- HY-105401
-
|
|
Bacterial
|
Infection
|
|
J-114870 is a bacterial penicillin-binding protein (PBPs) inhibitor. J-114870 is effective against methicillin-resistant Staphylococcus aureus (MRSA) and methicillin-resistant coagulase-negative staphylococci (MRCoNS). J-114870 can be used for research on bacterial infections .
|
-
- HY-183291
-
|
|
Bacterial
DNA/RNA Synthesis
DNA Alkylator/Crosslinker
Reactive Oxygen Species (ROS)
Penicillin-binding protein (PBP)
|
Infection
|
|
Antibacterial agent 343 (Compound 47) is an Antibacterial agent. Antibacterial agent 343 binds to the allosteric site of PBP2a to open its active site. Antibacterial agent 343 disrupts bacterial cell membranes, leading to protein leakage. Antibacterial agent 343 interacts with DNA and inhibits replication and transcription. Antibacterial agent 343 induces ROS accumulation. Antibacterial agent 343 exhibits antibacterial activity against MRSA, Staphylococcus aureus, and Enterococcus faecalis. Antibacterial agent 343 can be used for the research of methicillin-resistant Staphylococcus aureus infections .
|
-
- HY-N14119
-
|
|
Bacterial
|
Infection
|
|
Chloropolysporin C has strong activity of anti-Gram-positive bacteria, including methicillin-resistant Staphylococcus aureus (MRSA) and enterococcus bacteria .
|
-
- HY-182798
-
|
|
Bacterial
Reactive Oxygen Species (ROS)
|
Infection
|
|
Antibacterial agent 337 is an antibacterial agent. Antibacterial agent 337 specifically interacts with PG in bacterial cell membranes, triggering membrane disruption, membrane depolarization, increased permeability, cytoplasmic leakage, ROS accumulation and rapid bacterial death. Antibacterial agent 337 inhibits biofilm formation and disrupts mature biofilms. Antibacterial agent 337 exhibits potent in vivo antibacterial efficacy in a mouse model of Staphylococcus aureus skin abscess. Antibacterial agent 337 can be used in studies of Gram-positive bacterial infections, including methicillin-resistant Staphylococcus aureus infections, vancomycin-resistant Enterococcus faecalis infections and bacterial biofilm infections .
|
-
- HY-18704
-
|
(+)-Cyslabdan
|
Others
|
Infection
|
|
Cyslabdan ((+)-Cyslabdan) is a novel compound with the potential to enhance the activity of imipenem against methicillin-resistant Staphylococcus aureus. Cyslabdan exerts its antibacterial effect by inhibiting the synthesis of pentapeptide cross-links .
|
-
- HY-N5196
-
|
Nocathiacine I
|
Bacterial
|
Infection
|
|
Nocathiacin I (Nocathiacine I) is highly resistant to Gram-positive bacteria, including methicillin-resistant Staphylococcus aureus (MRSA), penicillin-resistant Streptococcus pneumoniae (PRSP) and multidrug resistant Enterococcus faecalis (MREF) .
|
-
- HY-N16526
-
|
|
Bacterial
|
Infection
|
|
Juncatrin B is a type of dihydrophenanthrene compound. Juncatrin B exhibits inhibitory activity against both Methicillin (HY-121544)-sensitive Staphylococcus aureus (MSSA) and Methicillin-resistant Staphylococcus aureus (MRSA). Juncatrin B can inhibit the formation of biofilms in MSSA and MRSA. Juncatrin B has no significant activity against Gram-negative bacteria. Juncatrin B can be used in the research of anti-Staphylococcus aureus .
|
-
- HY-N9833
-
|
|
Bacterial
|
Infection
|
|
Sampsone B is a dihydrodibenzodioxinone-type antibacterial agent with a minimum inhibitory concentration (MIC) of ≥128 μg/mL against methicillin-resistant Staphylococcus aureus (MRSA). Sampsone B can be naturally extracted from the aerial parts (stems and leaves) of Hypericum sampsonii .
|
-
- HY-N14172
-
|
|
Bacterial
Fungal
|
Infection
|
|
Epicorazine B has activity against Gram-positive bacteria, including methicillin-resistant Staphylococcus aureus (MRSA) and vancomycin resistant enterococcus (VRE), MICs of 12.5-25 μg/mL. Epicorazine B also has effect on Candida albicans with a MIC of 25 μg/mL .
|
-
- HY-N9819
-
|
|
Bacterial
|
Infection
|
|
Jinflexin D is a potential antibacterial agent, without inhibitory activity against methicillin-resistant Staphylococcus aureus (MRSA). Jinflexin D is a dimeric phenanthrene natural product with a unique seven-membered ring system, naturally extracted from the methanol extract of the roots of Juncus inflexus (a plant of the Juncaceae family) .
|
-
- HY-105523
-
|
|
Bacterial
|
Infection
|
|
S 3578 sulfate is a broad-spectrum antibacterial agent, particularly effective against methicillin-resistant Staphylococcus aureus (MRSA) (MIC = 0.78-3.13 μg/mL) and Pseudomonas aeruginosa (MIC = 1.56-6.25 μg/mL). S 3578 sulfate can be used in the research of infectious conditions .
|
-
- HY-N14530
-
|
|
Bacterial
|
Infection
Cancer
|
|
Cremeomycin has anti-Gram-positive bacteria activity including methicillin-resistant Staphylococcus aureus (MRSA), MIC is 0.2-0.39 μg/mL. Cremeomycin shows cytotoxicity to mouse tumor cell lines P388, L1210, IMC, S180, B16 and SS3 in vitro .
|
-
- HY-181100
-
|
|
Dihydrofolate reductase (DHFR)
Bacterial
|
Infection
|
|
DHFR-IN-26 is an Escherichia coli dihydrofolate reductase (ecDHFR) inhibitor with an IC50 of 0.75 nM. DHFR-IN-26 exerts broad-spectrum antibacterial activity. DHFR-IN-26 disrupts folate metabolism, nucleotide synthesis, and bacterial amino acid metabolic pathways. DHFR-IN-26 disrupts bacterial inner membranes, inhibited biofilm formation, and attenuated phage-related processes. DHFR-IN-26 shows lower toxicity to non-cancerous cells. DHFR-IN-26 can be used for the research of bacterial infections (including infections caused by methicillin-resistant Staphylococcus aureus, multidrug-resistant Escherichia coli, multidrug-resistant Pseudomonas aeruginosa, and lysogenic bacteria) .
|
-
- HY-N14484
-
|
|
Bacterial
|
Infection
Cancer
|
|
Kigamicin D shows activity against Gram-positive bacteria including methicillin-resistant Staphylococcus aureus (MRSA) with MICs of 0.025-0.78 μg/mL. Kigamicin D also shows effect against L-1210 LB32T and other genera tumor cells with IC50 of 1 μg/mL .
|
-
- HY-N0241
-
|
|
Cholinesterase (ChE)
Lipase
Bacterial
Cytochrome P450
|
Infection
Metabolic Disease
|
|
Rhodionin is an orally active, multifunctional antivirulence and cytoprotective agent that targets and inhibits Lipase, sortase A (SrtA), CYP2D6 (IC50=0.761 μM), AChE (IC50=2.43-57.5 μM), and DPPH free radicals (IC50=19.49 μM). Rhodionin is isolable from the roots of Rhodiola crenulata. Rhodionin reduces postprandial serum triglyceride levels in mice by inhibiting lipase activity. Rhodionin also binds directly to SrtA to inhibit its transpeptidase activity, thereby reducing the fibrinogen adhesion and surface protein A levels of MRSA, effectively inhibiting biofilm formation and protecting against MRSA-induced cell damage. Rhodionin improves the survival rate of infected mice without affecting MRSA growth, and finds wide application in studies related to hyperlipidemia, exogenous obesity, and pneumonia induced by methicillin-resistant Staphylococcus aureus (MRSA) .
|
-
- HY-14926R
-
|
(S)-(-)-Nadifloxacin (Standard); WCK 771 (Standard)
|
Reference Standards
Antibiotic
Bacterial
|
Infection
|
|
Levonadifloxacin (Standard) is the analytical standard of Levonadifloxacin. This product is intended for research and analytical applications. Levonadifloxacin ((S)-(-)-Nadifloxacin; WCK 771) is a broad-spectrum anti-staphylococcal agent. Levonadifloxacin shows antibacterial activity against Methicillin (HY-121544)-susceptible Staphylococcus aureus (MSSA) and Methicillin-resistant S. aureus (MRSA) strains, with a reduction of which phagocytized in THP-1 monocytes .
|
-
- HY-111023
-
|
TG-873870 malate
|
Antibiotic
Bacterial
|
Infection
|
|
Nemonoxacin (TG-873870) malate is a nonfluorinated quinolone antibiotic. Nemonoxacin malate has broad-spectrum activity against Gram-positive, Gram-negative and atypical pathogens. Nemonoxacin malate can inhibit drug-resistant Streptococcus pneumoniae and Methicillin-resistant Staphylococcus aureus. Nemonoxacin malate can be used for the research of community-acquired pneumonia .
|
-
- HY-143326
-
|
|
Bacterial
|
Infection
|
|
Antibacterial agent 83 (compound 17h) displays potent antibacterial activity against various vancomycin-resistant Enterococcus faecalis (VRE) and methicillin-resistant Staphylococcus aureus (MRSA). Antibacterial agent 83 can significantly reduce the biofilm formation of MRSA and exhibited promising selectivity. Antibacterial agent 83 is metabolically stable in human liver microsomes .
|
-
- HY-121000
-
|
Ingramycin
|
Antibiotic
Bacterial
|
Infection
|
|
Albocycline (Ingramycin) is a macrolide antibiotic, which exhibits antibacterial activities against methicillin-resistant Staphylococcus aureus (MRSA), Vancomycin (HY-B0671)-intermediate (VISA), and Vancomycin (HY-B0671)-resistant S. aureus (VRSA) strains with MICs ranging from 0.5 to 1.0 μg/mL. Albocycline exhibits no toxicity to human cells at concentration of ≤64 μg/mL .
|
-
- HY-174158
-
|
|
Bacterial
|
Infection
|
|
Antibacterial agent 270 (Compound 3e) is an antibacterial agent that acts on bacterial membrane components phosphatidylglycerol (PG), cardiolipin (CL), and bacterial DNA. Antibacterial agent 270 disrupts bacterial membrane structure and binds to DNA to interfere with genetic information transmission. Antibacterial agent 270 is promising for research of infections caused by methicillin-resistant Staphylococcus aureus (MRSA) .
|
-
- HY-112959
-
|
TD-6424
|
Antibiotic
Bacterial
|
Infection
|
|
Telavancin (TD-6424) is a semisynthetic lipoglycopeptide vancomycin-derivative, is a novel antimicrobial agent developed by Theravance for overcoming resistant Gram-positive bacterial infections, specifically methicillin-resistant Staphylococcus aureus (MRSA). Telavancin disrupts cell membrane integrity, can be used for research of complicated skin and skin structure infections (cSSSIs) caused by Gram-positive bacteria .
|
-
- HY-144823
-
|
|
Bacterial
|
Infection
|
|
Anti-MRSA agent 3 (compound 18) has highly inhibitory activity against Methicillin-resistant Staphylococcus aureus (MRSA) with MIC of 0.098 μg/ml, and low cytotoxicity in normal cells. Anti-MRSA agent 3 has relatively strong ability to destroy bacterial cell wall and membrane, high binding affinity to bacterial genomic DNA .
|
-
- HY-N11879
-
|
|
Bacterial
Antibiotic
|
Others
|
|
6-C-Methylquercetin-3,4'-dimethyl etheris a flavonol derivative isolated from the leaves of Bauhinia thonningii Schum. 6-C-Methylquercetin-3,4'-dimethyl ether has antibacterial activity against Gram-negative multidrug-resistant bacteria and against methicillin-resistant Staphylococcus aureus (MRSA) strains .
|
-
- HY-173478
-
|
|
Topoisomerase
Bacterial
Antibiotic
|
Infection
|
|
OSUAB-0284 is a bacterial topoisomerase inhibitor. OSUAB-0284 has significant anti-staphylococcal activity, especially against methicillin-resistant Staphylococcus aureus (MRSA). OSUAB-0284 exerts its antibacterial effect by inhibiting bacterial topoisomerase. OSUAB-0284 can be used to study infections caused by drug-resistant bacteria such as MRSA .
|
-
- HY-17626C
-
|
(R)-WCK-2349
|
Antibiotic
|
Others
|
|
(R)-Alalevonadifloxacin mesylate is an isomer of Alalevonadifloxacin mesylate (HY-17626B). Alalevonadifloxacin mesylate is a oraly active anti-methicillin-resistant Staphylococcus aureus (MRSA) antibiotic .
|
-
- HY-N15272
-
-
- HY-173225
-
|
|
Bacterial
|
Infection
|
|
MRSA/VRE-IN-1 (Compound 3e) is an inhibitor against methicillin-resistant Staphylococcus aureus (MRSA) and vancomycin-resistant Enterococcus (VRE). The MIC/MBC of MRSA/VRE-IN-1 against VRE is 3.6/7.3 µM, and against MRSA is 7.3/14.6 µM. MRSA/VRE-IN-1 can be used in the research of the anti-infection field .
|
-
- HY-13067
-
-
- HY-W112166
-
|
|
Parasite
Drug Isomer
|
Infection
|
|
(E/Z)-4,4'-Dicyanostilbene is the isomer of 4,4'-Dicyanostilbene (HY-W112166A), and can be used as an experimental control. 4,4'-Dicyanostilbene (compound 43) is a potent antimalarial agent against the Dd2 strain, with an EC50 of 27 nM. 4,4'-Dicyanostilbene exhibits in vivo efficacy against methicillin-resistant Staphylococcus aureus (MRSA) .
|
-
- HY-W250308A
-
|
Epsilon-polylysine hydrochloride (MV 2000-5000); ε-Polylysine hydrochloride (MV 2000-5000); ε-PL hydrochloride (MV 2000-5000)
|
Bacterial
Fungal
Reactive Oxygen Species (ROS)
|
Infection
|
|
ε-Poly-L-lysine (Epsilon-polylysine; ε-Polylysine) hydrochloride (MV 2000-5000) is a polycationic antibacterial agent with broad-spectrum activity against Gram-positive bacteria, Gram-negative bacteria, fungi, yeasts and specific bacteriophages. ε-Poly-L-lysine hydrochloride (MV 2000-5000) exerts bactericidal effects through mechanisms such as disrupting microbial membranes, inducing ROS production, inhibiting metabolism and spore germination. ε-Poly-L-lysine hydrochloride (MV 2000-5000) also regulates the expression of multiple key genes including sodA, oxyR and recA. ε-Poly-L-lysine hydrochloride (MV 2000-5000) exhibits properties such as low eukaryotic cytotoxicity, thermal stability and pH stability, and supports tissue regeneration and anti-tumor applications. ε-Poly-L-lysine hydrochloride (MV 2000-5000) can be applied in research fields including bacterial and fungal infections, diabetic ulcers, and methicillin-resistant Staphylococcus aureus infections .
|
-
- HY-178493
-
|
|
Bacterial
|
Infection
|
|
Anti-MRSA agent 37 (Compound 5B) is an antibacterial agent against methicillin-resistant Staphylococcus aureus (MRSA) (MIC=0.25-0.5 μg/mL). Anti-MRSA agent 37 inhibits biofilm formation, disrupts cell wall integrit, attacks cell membrane and induces oxidative stress. Anti-MRSA agent 37 is promising for research of MRSA-related diseases such as skin infections .
|
-
- HY-14737A
-
|
TAK-599 hydrate; PPI0903 hydrate
|
Antibiotic
Bacterial
|
Infection
|
|
Ceftaroline fosamil hydrate is a potent cephalosporin antibiotic. Ceftaroline fosamil hydrateshows broad-spectrum activity against Gram-positive pathogens, including methicillin-resistant Staphylococcus aureus (MRSA) and multidrug-resistant Streptococcus pneumoniae, and common Gram-negative organisms. Ceftaroline fosamil hydrate has anti-infective activity, and can be used for the research of complicated skin and skin structure infections (cSSSIs) and community-acquired bacterial pneumonia (CABP) .
|
-
- HY-W060074
-
|
|
Endogenous Metabolite
Bacterial
Tyrosinase
PERK
|
Infection
Endocrinology
|
|
1-Acetyl-β-carboline is a metabolite of Streptomyces kasugaensis and antibacterial agent. 1-Acetyl-β-carboline increases tyrosinase activity, reduces ERK phosphorylation. 1-Acetyl-β-carboline exhibits antibacterial activity against methicillin-resistant Staphylococcus aureus (MRSA) strains with MICs ranging from 128 to 256 ug/mL. 1-Acetyl-β-carboline increases the melanin .
|
-
- HY-174333
-
|
|
Bacterial
Cytochrome P450
|
Infection
Cardiovascular Disease
|
|
CYP1A1-IN-1 (Compound 47) is a small-molecule cytochrome P4501A1 (CYP1A1) inhibitor. CYP1A1-IN-1 reduces the bacterial loads of methicillin-resistant Staphylococcus aureus (MRSA) and Acinetobacter baumannii by enhancing macrophage phagocytosis. CYP1A1-IN-1 is promising for research of sepsis caused by multidrug-resistant (MDR) bacteria .
|
-
- HY-163463
-
|
|
Phosphatase
Fungal
HIV
Bacterial
|
Infection
Metabolic Disease
|
|
PTP1B-IN-25 (Compound 19) is a PTP1B inhibitor with remarkable antiviral, antibacterial, and antidiabetic activities. PTP1B-IN-25 has IC50 values of 0.37 μM, 8.6 μM, 3.7 μM, and 29 μM against PTP1B, HIV, α-Glucosidase, and methicillin-resistant Staphylococcus aureus (MRSA) respectively .
|
-
- HY-16764A
-
|
JNJ-Q2 hydrochloride
|
Bacterial
|
Infection
Inflammation/Immunology
|
|
Acorafloxacin hydrochloride (JNJ-Q2 hydrochloride) is a broad-spectrum fluoroquinolone anti-bacterial drug being developed for the treatment of acute bacterial skin and skin-structure infections and community-acquired pneumonia . Acorafloxacin hydrochloride is an aminoethylidenylpiperidine fluoroquinolone that demonstrates antibacterial effect against numerous Gram-positive bacteria with a mean 0.12 mg/L MIC90 value . Acorafloxacin hydrochloride has potential for study of methicillin-resistant Staphylococcus aureus (MRSA) infections .
|
-
- HY-139398
-
TBI-223
1 Publications Verification
|
Antibiotic
Bacterial
|
Infection
|
|
TBI-223 is an orally active oxazolidinone antibiotic and an antimicrobial. TBI-223 shows activity against Mycobacterium tuberculosis (Mtb). TBI-223 exhibits an IC50 of 68 μg/mL for inhibiting mitochondrial protein synthesis (MPS) in HepG2 cells. TBI-223 is effective in three mouse models (bloodstream infection, skin infection, and bone infection) of methicillin-resistant staphylococcus aureus infection. TBI-223 can be used for the study of tuberculosis .
|
-
- HY-179405
-
|
|
Bacterial
|
Infection
|
|
Antibacterial agent 301 (compound 14c) is a pyridine-amide pleuromutilin derivative with broad-spectrum antibacterial and pronounced antimycoplasmal activity. Antibacterial agent 301 inhibits peptidyl transferase center (PTC), breaks down biofilms, and disrupts cell membranes in multidrug-resistant (MDR) bacteria. Antibacterial agent 301 exhibits activity in a systemic methicillin-resistant Staphylococcus aureus (MRSA) infection mouse model. Antibacterial agent 301 can be used for MDR bacterial infection research .
|
-
- HY-172912
-
|
|
Bacterial
|
Infection
|
|
Anti-MRSA agent 27 (compound 4a) is a potent anti-methicillin-resistant Staphylococcus aureus agent with a MIC of 0.0975 μmol/L. Anti-MRSA agent 27 disrupts MRSA biofilms and suppresses hemolytic toxin production .
|
-
- HY-W024297
-
|
|
Bacterial
|
Infection
|
|
VP-4509, an anti-methicillin‐resistant Staphylococcus aureus (MRSA) agent, with the MIC of 49.3 µM. VP-4509 also possesses high antibacterial activity towards gram-negative bacteria P. aeruginosa .
|
-
- HY-14737
-
|
TAK-599; PPI0903
|
Bacterial
Antibiotic
|
Infection
|
|
Ceftaroline fosamil (TAK-599), a cephalosporin derivative, is an N-phosphono proagent of anti-methicillin-resistant Staphylococcus aureus (MRSA) T-91825. Ceftaroline fosamil can be used for the research of MRSA infection .
|
-
- HY-146460
-
|
|
Reactive Oxygen Species (ROS)
|
Infection
|
|
Antimicrobial agent-2 (compound V-a) is a broad-spectrum antimicrobial agent, possessing inhibitory activity against various Gram-positive and -negative bacteria. Antimicrobial agent-2 has excellent inhibitory effect on Methicillin-resistant Staphylococcus aureus (MRSA) with a MIC of 1 μg/mL. Antimicrobial agent-2 can effectively damage the membrane and lead to the leakage of protein, also can induce the generation of ROS. Antimicrobial agent-2 exhibits low toxicity, no obvious resistance and good bioavailability .
|
-
- HY-16764
-
|
JNJ-Q2
|
Bacterial
Antibiotic
|
Infection
Inflammation/Immunology
|
|
Avarofloxacin (JNJ-Q2) is a broad-spectrum fluoroquinolone antibacterial agent being developed for the treatment of acute bacterial skin and skin-structure infections and community-acquired pneumonia with oral activity. Avarofloxacin (JNJ-Q2) is an aminoethylidenylpiperidine fluoroquinolone that demonstrates antibacterial effect against numerous Gram-positive bacteria with a mean 0.12 mg/L MIC90 value. Avarofloxacin (JNJ-Q2) has potential for treatment of methicillin-resistant Staphylococcus aureus (MRSA) infections .
|
-
- HY-147882
-
|
|
Bacterial
|
Infection
|
|
Anti-MRSA agent 6 (compound 3q6) is a potent anti-methicillin-resistant Staphylococcus aureus (anti-MRSA) agent. Anti-MRSA agent 6 shows low cytoxicity for MCF-7, A549 cells .
|
-
- HY-N10765
-
|
|
Bacterial
|
Inflammation/Immunology
Cancer
|
|
Salvinolone is active against methicillin-resistant Staphylococcus aureus (MRSA) and vancomycin-resistant Enterococcus (VRE). Salvinolone shows cytotoxic activity with an IC50 of 47.6 μM against the HL-60 tumor cell line for 72 h .
|
-
- HY-14738
-
|
TAK-599 free acid; PPI0903 free acid
|
Bacterial
Antibiotic
|
Infection
|
|
Ceftaroline fosamil (inner) (TAK-599 free acid), a cephalosporin derivative, is an N-phosphono proagent of anti-methicillin-resistant Staphylococcus aureus (MRSA) T-91825. Ceftaroline fosamil (inner) can be used for the research of MRSA infection .
|
-
- HY-158402
-
|
|
Bacterial
Fungal
|
Infection
Inflammation/Immunology
|
|
Anti-inflammatory agent 84 (Compound 4D) is a derivative of Coumarin (HY-N0709) with antimicrobial and anti-inflammatory activities. Anti-inflammatory agent 84 inhibits E. coli, Candida albicans, Staphylococcus aureus and methicillin-resistant S. aureus (MRSA), with MIC of 312, 156, 19 and 316 μg/mL, respectively. Anti-inflammatory agent 84 inhibits biofilm formation of S. aureus, E. coli and MRSA, with IC50 of 185, 321 and 99 μM, respectively. Anti-inflammatory agent 84 inhibits nitric oxide production in Lipopolysaccharide (HY-D1056)-stimulated RAW264.7 macrophage cell .
|
-
- HY-173318
-
|
|
Bacterial
|
Infection
|
|
Anti-MRSA agent 25 (Compound 10c) is an antibacterial agent with a MIC of 0.25 μg/mL against methicillin-resistant Staphylococcus aureus (MRSA). Anti-MRSA agent 25 exerts its antibacterial activity by inhibiting biofilm formation, disrupting the cell wall (interacting with peptidoglycan and lipoteichoic acids), acting on the cell membrane (causing depolarization, increasing permeability, and disrupting integrity), reducing metabolic activity, interfering with cellular redox homeostasis, and binding to DNA. Anti-MRSA agent 25 is expected to be used in the research of the anti-infection field .
|
-
- HY-N10834
-
|
|
Bacterial
|
Infection
|
|
(6E,12E)-Tetradecadiene-8,10-diyne-1,3-diol is an antibacterial compound. (6E,12E)-Tetradecadiene-8,10-diyne-1,3-diol can be isolated from the roots of Atractylodes japonica. (6E,12E)-Tetradecadiene-8,10-diyne-1,3-diol has anti-methicillin-resistant Staphylococcus aureus (MRSA) activity with MIC values of 4-32 μg/mL. (6E,12E)-Tetradecadiene-8,10-diyne-1,3-diol can be used for the research of bacterial infection . (6E,12E)-Tetradecadiene-8,10-diyne-1,3-diol is a click chemistry reagent, it contains an Alkyne group and can undergo copper-catalyzed azide-alkyne cycloaddition (CuAAc) with molecules containing Azide groups.
|
-
- HY-N10907
-
|
|
Bacterial
|
Infection
|
|
4(1H)-Quinolinone, 1-methyl-2-(5Z)-5-undecen-1-yl- (compound 2) is a quinolone alkaloid that can be isolated from Cnidium. 4(1H)-Quinolinone, 1-methyl-2-(5Z)-5-undecen-1-yl- has methicillin-resistant Staphylococcus aureus (MRSA) activity, with MIC values of 32 μg/mL (ATCC 33591) and 16 μM/mL (ATCC 25923), respectively .
|
-
- HY-13067G
-
|
Tripterine; Tripterin
|
Endogenous Metabolite
Proteasome
Antibiotic
Apoptosis
Bacterial
Autophagy
Mitophagy
|
Infection
Inflammation/Immunology
Cancer
|
|
Celastrol (GMP) (Tripterine (GMP)) is Celastrol (HY-10227) produced by using GMP guidelines. GMP small molecules works appropriately as an auxiliary reagent for cell therapy manufacture. Celastrol (Tripterine;Tripterin) is a proteasome inhibitor which potently and preferentially inhibits the chymotrypsin-like activity of a purified 20S proteasome with IC50 of 2.5 μM. In addition, Celastrol is also an antibiotic with potent antimicrobial activity against standard and clinical methicillin-resistant Staphylococcus aureus (MRSA) strains, inducing oxidative stress and inhibiting DNA synthesis by binding to P5CDH .
|
-
- HY-179611
-
|
|
Bacterial
|
Infection
|
|
LP-03 is an antibacterial agent with selective activity against Methicillin-resistant Staphylococcus aureus (MRSA). Its minimum inhibitory concentration (MIC) is 6.2 μM. LP-03 has an inhibitory effect on biofilm formation, but it is unable to effectively remove the formed biofilms. LP-03 can enhance membrane permeability, disrupt the membrane structure of MRSA cells, and does not cause significant membrane depolarization. LP-03 has no hemolytic toxicity and shows low mammalian cell toxicity. It can be used for research on MRSA infections .
|
-
- HY-174459
-
|
|
Bacterial
Penicillin-binding protein (PBP)
|
Infection
|
|
Anti-MRSA agent 31 (Compound 6) is an anti-methicillin-resistant Staphylococcus aureus (MRSA) agent with a MIC of 97 μg/mL and a MBC of 781.25 μg/mL. Anti-MRSA agent 31 has a potent antibacterial activity and a strong Binding Protein 2a (PBP2a) inhibitory activity .
|
-
- HY-179059
-
|
|
Bacterial
Reactive Oxygen Species (ROS)
|
Infection
|
|
Anti-MRSA agent 40 (Compound 7-8) is a potent agent against Methicillin-resistant Staphylococcus aureus (MRSA). Anti-MRSA agent 40 exhibits significant antibacterial activity against MRSA2 and S. aureus ATCC 29213, with its MIC values being 1 μg/mL. Anti-MRSA agent 40 causes depolarization of the cell membrane, damages membrane integrity, and simultaneously increases the level of ROS within MRSA2, ultimately leading to cell lysis and death. Anti-MRSA agent 40 shows significant efficacy in the MRSA2 skin abscess model. Anti-MRSA agent 40 can be used for research on anti-MRSA infections .
|
-
- HY-161935
-
|
|
Bacterial
|
Infection
Inflammation/Immunology
|
|
6-(12-Tridecene-1-yl)-2,4-Dihydroxy benzoic acid (Compound 2) exhibits antibacterial activity against methicillin-resistant Staphylococcus aureus (MRSA) and Vancomycin enterococci (VRE). 6-(12-Tridecene-1-yl)-2,4-Dihydroxy benzoic acid interfers with the integrity and function of the bacterial cell membrane, and affects metabolism in MRSA. 6-(12-Tridecene-1-yl)-2,4-Dihydroxy benzoic acid exhibits anti-inflammatory and anti-infective efficacy, and promotes angiogenesis in mice .
|
-
- HY-113703
-
|
|
Antibiotic
|
Cancer
|
|
PD117588 is a quinolone antibacterial agent with a broad range of antibacterial activity. PD117588 exhibits excellent activity against a variety of Gram-positive and Gram-negative bacteria from cancer patients, especially against all Gram-positive strains, including methicillin-resistant Staphylococcus aureus, coagulase-negative Staphylococci, and Enterococci. PD117588 is also very effective against most Gram-negative bacilli, although ciprofloxacin shows stronger activity against Pseudomonas aeruginosa. Compared with other quinolone antibiotics, the minimum inhibitory concentration of PD117588 outperforms most of the tested microorganisms, including imipenem and ceftazidime .
|
-
- HY-168873
-
|
|
Bacterial
|
Infection
|
|
Anti-MRSA agent 23 (compound 11) is a potent anti-methicillin-resistant Staphylococcus aureus agent. Anti-MRSA agent 23 shows antibacterial and antibiofilm activities. Anti-MRSA agent 23 accelerates the reconstruction and healing of MRSA-infected cutaneous wounds by decreasing bacterial loads, attenuating inflammation, and promoting angiogenesis .
|
-
- HY-14737R
-
|
TAK-599 (Standard); PPI0903 (Standard)
|
Reference Standards
Bacterial
Antibiotic
|
Infection
|
|
Ceftaroline fosamil (Standard) is the analytical standard of Ceftaroline fosamil. This product is intended for research and analytical applications. Ceftaroline fosamil (TAK-599), a cephalosporin derivative, is an N-phosphono proagent of anti-methicillin-resistant Staphylococcus aureus (MRSA) T-91825. Ceftaroline fosamil can be used for the research of MRSA infection[1][2][3].
|
-
- HY-127072
-
|
|
Antibiotic
Bacterial
|
Infection
Inflammation/Immunology
Cancer
|
|
Amicoumacin A is an orally active antibiotic. Amicoumacin A targets bacterial ribosomes and inhibits bacterial translation by stabilizing the interaction between mRNA and ribosomes. Amicoumacin A induces cancer cell death by targeting eukaryotic ribosomes. Amicoumacin A exhibits anti-inflammatory and anti-ulcer activities, inhibits carrageenan-induced paw edema, and prevents stress-induced gastric ulcers. Amicoumacin A inhibits the growth of Gram-positive bacteria, Salmonella spp., Shigella spp., Helicobacter pylori, and methicillin-resistant Staphylococcus aureus. Amicoumacin A can be used in the research of lung cancer, breast cancer, bacterial infections, inflammatory edema and gastric ulcers [2] .
|
-
- HY-156123
-
|
|
Dihydrofolate reductase (DHFR)
Bacterial
|
Infection
Cancer
|
|
DHFR-IN-9 (compound 8A) is a dihydrofolate reductase (DHFR) inhibitor that affects purine and thymidylate biosynthesis in cell proliferation and growth. DHFR-IN-9 inhibits methicillin-resistant Staphylococcus aureus (MRSA) ATCC 43300 (IC50=0.25 μg/mL) and has anti-infective effects in mouse models of systemic infection and thigh infection caused by it (dose: 2.5 mg /kg, 5 mg/kg; ip). DHFR-IN-9 has stronger anticancer activity than paclitaxel (Y-B0015) in a mouse model of breast cancer (dose: 2.5 mg/kg; ip; once every 3 days) .
|
-
- HY-69174
-
|
|
Bacterial
|
|
|
1-Amino-2,5-anhydro-1-deoxy-D-mannitol is a potent antibacterial compound with antibacterial activity against a variety of Gram-positive bacteria, including methicillin-resistant Staphylococcus aureus (MRSA) and vancomycin-resistant Enterococci (VRE). The application potential of 1-Amino-2,5-anhydro-1-deoxy-D-mannitol lies in its ability to effectively combat common drug-resistant bacterial infections. 1-Amino-2,5-anhydro-1-deoxy-D-mannitol may become an emerging antibacterial agent in clinical inhibition.
|
-
- HY-N10561
-
|
|
Bacterial
|
Infection
|
|
Wychimicin A is a spirotetronate polyketide, can be isolated from the rare actinomycete Actinocrispum wychmicini strain MI503-AF4. Wychimicin A shows strong antibacterial activity against methicillin-resistant Staphylococcus. aureus (IC50=0.125-0.5 μg/mL) and Enterococcus. faecalis/faecium (IC50=0.125-0.25 μg/mL) .
|
-
- HY-121300
-
|
(-)-TAN2162
|
Antibiotic
Bacterial
Endothelin Receptor
CGRP Receptor
|
Infection
Cancer
|
|
Kendomycin ((−)-TAN 2162) is a polyketide antibiotic with remarkable antibacterial and cancer cells cytotoxic activities. Kendomycin tends to be bacteriostatic rather than bactericidal and inhibits the growth of the methicillin-resistant Staphylococcus aureus (MRSA) strain COL at a low concentration (MIC of 5 μg/mL). Kendomycin is a potent antagonist of the endothelin receptor and a calcitonin receptor agonist which plays its role as an anti-osteoporotic agent .
|
-
- HY-183751
-
|
|
Bacterial
Reactive Oxygen Species (ROS)
|
Infection
|
|
Antibacterial agent 346 (Compound H14d) is a broad-spectrum Antibacterial agent and BsFtsZ inhibitor, with an IC50 of 69.67 μg/mL against BsFtsZ. Antibacterial agent 346 selectively binds to phosphatidylglycerol, disrupts membrane integrity, increases permeability, triggers depolarization and causes intracellular protein leakage. Antibacterial agent 346 induces intracellular ROS accumulation, which in turn triggers oxidative stress and cell death. Antibacterial agent 346 eradicates mature biofilms formed by Gram-positive and Gram-negative bacteria. Antibacterial agent 346 exhibits antibacterial activity against methicillin-resistant Staphylococcus aureus and Acinetobacter baumannii. Antibacterial agent 346 can be used in the research of bacterial infections .
|
-
- HY-N10560
-
|
|
Bacterial
|
Infection
|
|
Wychimicin C is a spirotetronate polyketide, can be isolated from the rare actinomycete Actinocrispum wychmicini strain MI503-AF4. Wychimicin C shows strong antibacterial activity against methicillin-resistant Staphylococcus. aureus (IC50=0.125-0.5 μg/mL) and Enterococcus. faecalis/faecium (IC50=0.125-0.25 μg/mL) .
|
-
- HY-10393
-
|
PNU-100592
|
Bacterial
Antibiotic
|
Infection
|
|
Eperezolid (PNU-100592) is an orally active protein synthesis inhibitor that targets the bacterial 50S ribosomal subunit. Eperezolid competitively binds to a specific site on the ribosomal 50S subunit (overlapping with the binding sites of chloramphenicol (HY-B0239) and lincomycin (HY-117660)) to inhibit the translation initiation stage and exert antibacterial activity. Eperezolid can induce host cell autophagy to enhance the clearance of intracellular mycobacteria, and its MIC90 for Staphylococcus aureus and Enterococcus is 1-4 μg/mL. Eperezolid is mainly used for antibacterial research on infections with Gram-positive bacteria such as methicillin-resistant (HY-121544) Staphylococci and vancomycin-resistant (HY-B0671) Enterococci, as well as infections with intracellular bacteria such as Mycobacterium tuberculosis .
|
-
- HY-147755
-
|
|
Bacterial
|
Infection
|
|
C16-K-cBB1 is a potent and selective antimicrobial agent for MRSA (Methicillin resistant Staphylococcus aureus), with a MIC of 1 µg/mL. C16-K-cBB1 has very good selectivity, as it has weak hemolytic activity. C16-K-cBB1 is able to kill MRSA cells in a matter of 120 min at a concentration of 12.5 μg/mL .
|
-
- HY-138137
-
|
|
Bacterial
|
Infection
|
|
Menaquinone 6 is a active product found in Wolinella succinogenes. Menaquinone 6 is a form of vitamin K2 (HY-109569) that has antimicrobial activity .
|
-
- HY-12770R
-
|
Mebeverine metabolite Mebeverine alcohol (Standard)
|
Reference Standards
Drug Metabolite
|
Neurological Disease
|
|
Mebeverine alcohol (Standard) is an analytical standard for Mebeverine alcohol. This product is intended for research and analytical applications. Eperezolid (PNU-100592) is an orally active protein synthesis inhibitor that targets the bacterial 50S ribosomal subunit. Eperezolid competitively binds to a specific site on the ribosomal 50S subunit (overlapping with the binding sites of Chloramphenicol (HY-B0239) and Lincomycin (HY-117660)) to inhibit the translation initiation stage and exert antibacterial activity. Eperezolid can induce host cell autophagy to enhance the clearance of intracellular mycobacteria, and its MIC90 for Staphylococcus aureus and Enterococcus is 1-4 μg/mL. Eperezolid is mainly used for antibacterial research on infections with Gram-positive bacteria such as methicillin-resistant (HY-121544) Staphylococci and vancomycin-resistant (HY-B0671) Enterococci, as well as infections with intracellular bacteria such as Mycobacterium tuberculosis .
|
-
- HY-146047
-
|
|
Bacterial
|
Infection
|
|
Antibacterial agent 94 (compound 5b) is a potent antibacterial agent. Antibacterial agent 94 show antibacterial activities and show the capability of eradicating MRSA persisters. Antibacterial agent 94 has an effect on bacterial membrane. Antibacterial agent 94 interferes in phosphatidylglycerol (PG) synthesis pathway .
|
-
- HY-P11607
-
|
|
Bacterial
|
Infection
|
|
CyLip-10 is a microbial-derived cyclic-lipid antimicrobial peptide. CyLip-10 has broad-spectrum antimicrobial efficacy, low hemolytic activity, and excellent stability. CyLip-10 can disrupt membrane integrity, inhibit biofilm formation and induce membrane permeabilization and bacterial cell death. CyLip-10 reduces bacterial load, promotes wound healing, and alleviates inflammatory responses in a mouse Methicillin (HY-121544)-resistant Staphylococcus aureus skin wound infection model. CyLip-10 can be used for the bacterial infection .
|
-
- HY-185443
-
|
|
Bacterial
Dihydrofolate reductase (DHFR)
|
Infection
|
|
UCP1172 is an antibacterial (Antibacterial) agent and Dihydrofolate reductase inhibitor, with an IC50 of 0.0089 μM against Staphylococcus aureus DfrB, 0.22 μM against DfrG, 0.41 μM against DfrA, and 0.030 μM against DfrK. UCP1172 potently inhibits the growth of MRSA/MSSA isolates carrying dfrG and dfrK (MIC values of 0.3125-0.625 μg/mL), shows weak activity against MRSA carrying dfrA (MIC of 5 μg/mL), and exerts extremely potent inhibitory effects on wild-type S. aureus ATCC 43300 (MIC of 0.0098 μg/mL). UCP1172 can be used in studies related to tuberculosis and Staphylococcus aureus infections .
|
-
- HY-N19293
-
|
|
Bacterial
|
Infection
|
|
Aquastatin C is a glycoaromatic derivative that can be found in Sporothrix sp. FN611. Aquastatin C is a substance that neither regulates bacterial enzymes nor inhibits bacterial growth .
|
-
- HY-144621
-
-
- HY-N19290
-
|
|
Bacterial
|
Infection
|
|
Glenthmycin E is an antibacterial agent found in Australian sheep pasture-derived Streptomyces sp. CMB-PB041. Glenthmycin E inhibits growth of multiple bacterial and exhibits no detectable cytotoxicity to eukaryotic cells including fungal and human carcinoma cells. Glenthmycin E can be used for the research of bacterial infections .
|
-
- HY-186194
-
|
|
Drug Derivative
|
Infection
|
|
6-Methoxy-γ-mangostin is a synthetic analogue of prenylated xanthone. 6-Methoxy-γ-mangostin can be used for research on bacterial infection .
|
-
- HY-180389
-
|
|
Drug Derivative
|
Others
|
|
3-Chloro-4-(octyloxy) aniline (Compound 299) is a phthalamide ester derivative. 3-Chloro-4-(octyloxy) aniline exhibits no antibacterial activity .
|
-
- HY-180191
-
|
|
Bacterial
Reactive Oxygen Species (ROS)
DNA/RNA Synthesis
|
Infection
|
|
Anti-MRSA agent 42 (Compound 6d) is an anti-methicillin-resistant Staphylococcus aureus (MRSA) agent. Anti-MRSA agent 42 shows strong inhibitory effects on MRSA standard strains and 11 clinical isolates with MIC values of 0.25-0.5 μg/mL. Anti-MRSA agent 42 has low hemolytic activity and minimal cytotoxicity toward mammalian cells. Anti-MRSA agent 42 can suppress biofilm formation, compromise the cell wall, and disrupt the cytoplasmic membrane, which are accompanied by membrane depolarization, enhanced permeability, and loss of membrane integrity. Anti-MRSA agent 42 can induce ROS production and bind to DNA grooves, interfering with nucleic acid function. Anti-MRSA agent 42 can be used for the research of MRSA infection .
|
-
- HY-183053
-
|
|
Bacterial
Dihydrofolate reductase (DHFR)
Antifolate
|
Infection
|
|
UCP1173, propargyl-linked antifolate, is an antibacterial agent. UCP1173 inhibits DHFR enzymes, with IC50 values of 0.014 μM for DfrB, 0.19 μM for DfrG, 0.27 μM for DfrA, and 0.091 μM for DfrK. UCP1173 inhibits growth of Staphylococcus aureus clinical isolates carrying dfrA, dfrG, or dfrK resistance genes. UCP1173 can be used for the research of bacterial infections .
|
-
- HY-182033
-
|
|
Bacterial
ClpP
|
Infection
|
|
ClpP agonist 1 is a Staphylococcus aureus ClpP (SaClpP) agonist with an EC50 of 1.44 μM, Kd values of 2.95 μM (isothermal titration calorimetry) and 18 μM (bio-layer interferometry), and a low drug resistance frequency. ClpP agonist 1 reduces bacterial load, shrinks infected area and improves histopathological outcomes in a mouse skin infection model. ClpP agonist 1 can be used for the research of Methicillin (HY-121544)-resistant Staphylococcus aureus (MRSA) skin infections .
|
-
- HY-153695
-
|
|
Bacterial
|
Infection
|
|
TXA707 is an FtsZ-targeting antibacterial agent. TXA707 disrupts bacterial septum formation, induces cell enlargement, causes penicillin-binding protein mislocalization, and triggers cell lysis in Staphylococcus aureus cells. TXA707 can be used for the research of Staphylococcus aureus infections .
|
-
- HY-P11191
-
|
|
Bacterial
|
Infection
|
|
AR-23 is a melittin-related antimicrobial peptide that can be isolated from Rana tagoi. AR-23 exhibits broad-spectrum growth inhibitory activity against aerobic bacteria, the opportunistic yeast pathogen Candida albicans and clinical isolates of Methicillin (HY-121544)-resistant Staphylococcus aureus (MRSA). AR-23 can be used for antimicrobial research .
|
-
- HY-126258
-
|
|
Bacterial
DNA/RNA Synthesis
|
Infection
|
|
IMP-1700 is a potent DNA damage potentiator and antibacterial agent. IMP-1700 inhibits the bacterial SOS response to DNA damage. IMP-1700 potently sensitizes MRSA to Ciprofloxacin (HY-B0356) with an EC50 of 5.9 nM. IMP-1700 inhibits the growth of E. coli K-12 BW25113, S. aureus SH1000 and MRSA USA300 JE2 .
|
-
- HY-130052
-
|
|
Bacterial
|
Infection
|
|
Rosellichalasin is an antibacterial agent isolated from the endophytic fungus Aspergillus flavipes Y-62. Rosellichalasin exhibits antibacterial activity .
|
-
- HY-P11616
-
|
|
Bacterial
TNF Receptor
|
Infection
|
|
WK2 is an antibacterial agent. WK2 reduces serum TNF-α production induced by Bacterial infection. WK2 reduces wound size and promotes tissue repair in a skin wound infection model. WK2 exerts anti-inflammatory effects in a pneumonia model. WK2 can be used for research on infectious diseases such as pneumonia caused by bacterial infection .
|
-
- HY-162761
-
|
|
Bacterial
COX
|
Inflammation/Immunology
|
|
COX-1/2-IN-9 (Compound 3n) is a potent and selective inhibitor of COX-1/2, with IC50 values of 0.031 µM and 0.01 µM, respectively. COX-1/2-IN-9 possesses both antibacterial and anti-inflammatory activities, effectively inhibiting MRSA 1478 (MIC=50 μg/mL) and multidrug-resistant S. lentus (MIC=50 μg/mL). COX-1/2-IN-9 holds significant potential to alleviate MRSA-induced pneumonia in immunocompromised states .
|
-
- HY-P10486
-
|
|
Bacterial
|
Infection
|
|
AIP-II is a cyclic peptide signaling molecule for quorum sensing, which is produced by Staphylococcus aureus. AIP-II potently inhibits AgrC-III in Methicillin (HY-121544)-resistant type III Staphylococcus aureus strain AH1747, with an IC50 of 0.532 nM. AIP-II binds to the AgrC-II receptor and regulates virulence gene expression in Staphylococcus aureus .
|
-
- HY-W033728
-
|
|
Bacterial
|
Infection
|
|
Platinum(COD)dichloride (Compound Pt1) is an Antibacterial agent. Platinum(COD)dichloride shows antibacterial activity against a panel of gram-positive bacteria including Vancomycin (HY-B0671) and Methicillin (HY-121544) resistant Staphylococcus aureus .
|
-
- HY-182823
-
|
|
Drug Derivative
Bacterial
|
Infection
|
|
N-Nitrosovancomycin is an antibacterial agent and an N-terminal nitrosated derivative of vancomycin. N-Nitrosovancomycin exhibits antibacterial activity against Gram-positive bacteria in vitro, but shows no activity against Gram-negative E. coli. The modified N-terminal amino group of N-Nitrosovancomycin cannot be protonated, yet the compound still retains in vitro antibacterial activity. N-Nitrosovancomycin can be used in studies related to Gram-positive bacterial infections .
|
-
- HY-149734
-
|
|
Bacterial
|
Infection
|
|
MA220607 is a FtsZ protein inhibitor with activity against both Gram-positive and Gram-negative bacteria. MA220607 inhibits bacterial growth and shows low bacterial resistance frequency. MA220607 increases bacterial membrane permeability and alters proton gradients. MA220607 blocks the formation of bacterial biofilms. MA220607 can be used in studies of bacterial infections .
|
-
- HY-B0771
-
|
SCE-2787
|
Antibiotic
Bacterial
Penicillin-binding protein (PBP)
|
Infection
|
|
Cefozopran (SCE-2787) is a potent antibiotic with broad-spectrum antibacterial activity. Cefozopran binds PBPs, induces cell wall destruction, cell elongation, filamentation, irregular septa formation, and bactericidal, bacteriolytic activity. Cefozopran reduces bacterial counts and eradicates bacteria in mouse respiratory, urinary, and thigh muscle infections. Cefozopran can be used for the research of bacterial infections .
|
-
- HY-W740077
-
|
SCE-2787 dihydrochloride
|
Antibiotic
Bacterial
Penicillin-binding protein (PBP)
|
Infection
|
|
Cefozopran (SCE-2787) dihydrochloride is a potent antibiotic with broad-spectrum antibacterial activity. Cefozopran dihydrochloride binds PBPs, induces cell wall destruction, cell elongation, filamentation, irregular septa formation, and bactericidal, bacteriolytic activity. Cefozopran dihydrochloride reduces bacterial counts and eradicates bacteria in mouse respiratory, urinary, and thigh muscle infections. Cefozopran dihydrochloride can be used for the research of bacterial infections .
|
-
- HY-B0771A
-
|
SCE-2787 hydrochloride
|
Antibiotic
Bacterial
Penicillin-binding protein (PBP)
|
Infection
|
|
Cefozopran (SCE-2787) hydrochloride is a potent antibiotic with broad-spectrum antibacterial activity. Cefozopran hydrochloride binds PBPs, induces cell wall destruction, cell elongation, filamentation, irregular septa formation, and bactericidal, bacteriolytic activity. Cefozopran hydrochloride reduces bacterial counts and eradicates bacteria in mouse respiratory, urinary, and thigh muscle infections. Cefozopran hydrochloride can be used for the research of bacterial infections .
|
-
- HY-N16403
-
|
|
Cytochrome P450
Endogenous Metabolite
Bacterial
Insecticide
Fungal
|
Infection
Cancer
|
|
Aspergillusidone F is a Depsidone and antibacterial agent. Aspergillusidone F can be isolated from a marine fungus Aspergillus unguis. Aspergillusidone F potently inhibits Aromatase with an IC50 of 0.5 μM. Aspergillusidone F exhibits antibacterial activity against Pseudomonas aeruginosa and Methicillin (HY-121544)-resistant Staphylococcus aureus. Aspergillusidone F exhibits potent larvicidal activity against Artemia salina larvae, with an LC50 value of 12.8 μM. Aspergillusidone F exhibits anticancer activity against intrahepatic cholangiocarcinoma, non-small cell lung cancer, and acute lymphoblastic leukemia .
|
-
- HY-N15755
-
|
|
Bacterial
Fungal
|
Infection
|
|
Sepiumol A is a polyphenolic compound that can be isolated from the bark of Periploca sepium Bunge. Sepiumol A has antibacterial and antifungal activities. Sepiumol A can be added to e-cigarette liquid to exert antibacterial effects and reduce the sweetness and greasiness during smoking .
|
-
- HY-P11615
-
|
|
Bacterial
|
Infection
|
|
FuK is a WK2-analog antimicrobial peptide modified with fluorinated unnatural amino acids. FuK has an LD50 of 72.34 mg/kg in mice, shows no hemolytic activity, with high stability against trypsin, chymotrypsin, and saline environments. FuK exerts bactericidal effects by enhancing the permeability of bacterial outer membranes, inducing depolarization of cytoplasmic membranes, and disrupting membrane potential balance against bacterias such as Staphylococcus aureus, Escherichia coli, Klebsiella pneumoniae, and MRSA. FuK exhibits synergistic antimicrobial activity with polymyxin B (HY-149179), vancomycin (HY-B0671), and ciprofloxacin (HY-B0356), and also inhibits Ciprofloxacin-induced bacterial drug resistance. FuK has in vivo safety, effectively reduces bacterial load and inflammatory cell infiltration in a mouse MRSA model, and promotes collagen fiber formation in skin wounds .
|
-
- HY-182027
-
|
|
Bacterial
Reactive Oxygen Species (ROS)
Lactate Dehydrogenase
DNA/RNA Synthesis
|
Infection
|
Antibacterial agent 330 is an antibacterial agent. Antibacterial agent 330 triggers ROS accumulation, forms DNA supramolecular complex by intercalation to block DNA replication and inhibits LDH to disturb metabolism, and further prompts bacterial cell rupture to induce the leakage of intracellular content, ultimately causing bacterial death. Antibacterial agent 330 displays antibacterial activity and promotes wound healing in both G. Mellonella larval and murine wound infection models. Antibacterial agent 330 can be used for the research of bacterial infections .
|
-
- HY-N14145
-
|
|
Antibiotic
Bacterial
|
Infection
|
|
Collinone is a recombinant angular polyketide antibiotic. Collinone shows antibacterial activities for gram-positive bacterial. Collinone shows cytotoxicity .
|
-
- HY-N18102
-
|
|
Bacterial
|
Infection
|
|
3,4-Seco-mansumbinoic acid (Compound 2) is an Antibacterial agent. 3,4-Seco-mansumbinoic acid can be isolated from the oleo-resin of Commiphora molmol. 3,4-Seco-mansumbinoic acid exhibits in vitro anti-staphylococcal activity, with the strongest activity against the multidrug-resistant Staphylococcus aureus strain SA-1199B (MIC 4 μg/mL) 3,4-Seco-mansumbinoic acid displays weak potentiation of Ciprofloxacin (HY-B0356) and Tetracycline (HY-A0107) activity against strains of Salmonella enterica serovar Typhimurium SL1344 and L10. 3,4-Seco-mansumbinoic acid can be used for the research of multidrug-resistant bacterial infection (Staphylococcus aureus, Salmonella enterica serovar Typhimurium) .
|
-
- HY-W040128
-
|
|
Antibiotic
Autophagy
JNK
Bcl-2 Family
|
Infection
|
|
Kanamycins sulfate is a blood-brain barrier-permeable JNK1 and Bcl-2 modulator as well as an antibiotic, with broad-spectrum antibacterial, and biofilm-inhibiting activities, and it induces autophagy. Kanamycins sulfate promotes Bcl-2 phosphorylation to upregulate autophagy levels, triggering changes such as mitochondrial swelling and endoplasmic reticulum expansion. Consequently, it causes reversible neuronal damage in the dorsal cochlear nucleus without inducing significant neuronal apoptosis. In the presence of exogenous alanine or glucose, Kanamycins sulfate effectively kills drug-resistant bacteria, restores drug sensitivity of multidrug-resistant bacteria, and alleviates urinary tract and kidney infections in mice. Kanamycins sulfate can be applied to scientific research related to Mycobacterium tuberculosis, salmonellosis, brucellosis, shigellosis, urinary tract infections, and reversible neurotoxicity .
|
-
- HY-P2460
-
|
|
Bacterial
Fungal
Interleukin Related
TNF Receptor
|
Infection
Inflammation/Immunology
|
|
SMAP‑29 is a cathelicidin antimicrobial peptide with LPS‑binding and anti‑inflammatory properties. SMAP‑29 exerts broad‑spectrum antimicrobial activity against bacteria, fungi and multidrug‑resistant isolates. SMAP‑29 kills pathogens by permeabilizing bacterial membranes, inducing depolarization and cell lysis, and also inhibits inflammatory cytokines while reducing lethality in septic shock and pneumonia models. SMAP-29 can be used for research on bacterial infections, drug-resistant infections, septic shock .
|
-
- HY-123779
-
|
|
Bacterial
Fungal
|
Infection
|
|
RWJ-49815 is a histidine kinase inhibitor. RWJ-49815 inhibits the autokinase activity of purified GST-Sln1 and the autophosphorylation of KinA in vitro. RWJ-49815 acts as a fungal growth inhibitor . RWJ-49815 serves as a bactericide against Gram-positive pathogenic bacteria. RWJ-49815 is applicable to research related to fungal infections and Gram-positive bacterial infections .
|
-
- HY-N19220
-
|
|
Bacterial
Endogenous Metabolite
Antibiotic
|
Infection
Cancer
|
|
Radiclonic acid acts as an antibacterial agent, anticancer agent, and root growth promoter. Radiclonic acid is isolable from fungi of the genus Penicillium. Radiclonic acid exhibits antibacterial activity against MRSA with a MIC of 3.13 μg/mL. Radiclonic acid shows anticancer activity against esophageal cancer, bladder cancer, and liver cancer. Radiclonic acid promotes root growth in Chinese cabbage seedlings. Radiclonic acid is inactive against pancreatic cancer and cervical cancer. Radiclonic acid can be used in research related to Staphylococcus aureus infection, bladder cancer, esophageal cancer, and liver cancer .
|
-
- HY-182816
-
|
|
Topoisomerase
DNA/RNA Synthesis
Bacterial
|
Infection
|
|
Topoisomerase I-IN-22 is an inhibitor of MRSA DNA Topoisomerase I with an IC50 of 0.85 μg/mL. Topoisomerase I-IN-22 can specifically disrupt the cell membrane structure of MRSA, enter the interior of bacteria and inhibit the activity of DNA Topoisomerase I, thereby interfering with the processes of DNA replication and transcription. Topoisomerase I-IN-22 can be used for the research of MRSA infection .
|
-
- HY-102072
-
|
|
Bacterial
DNA/RNA Synthesis
|
Infection
|
|
GKL003 is a bacterial transcription inhibitor that targets the RNAP-σ interaction interface, with a Ki of 5.79 nM. GKL003 specifically binds to the RNAP β' clamp helix region at the σ A factor binding site, blocks the formation of RNAP holoenzyme, and inhibits the formation of bacterial transcription initiation complexes. GKL003 inhibits the growth of both Gram-positive and Gram-negative bacterial cells, and also exhibits activity against drug-resistant strains .
|
-
- HY-W142206
-
|
|
Fungal
|
Infection
|
|
Cyclopent-4-ene-1,3-dione is a potent antifungal inhibitor of chitin synthesis. Cyclopent-4-ene-1,3-dione is potently antifungal against human pathogenic Candida species (IC50 = 1-2 μM). Cyclopent-4-ene-1,3-dione is detected in feijoa cultivars with high antifungal bioactivity. Cyclopent-4-ene-1,3-dione can be used for the research of fungal infections .
|
-
- HY-N17297
-
|
|
Fungal
|
Infection
|
|
Leotiomycene C is an isoprenylated bisresorcinol natural product present in the freshwater fungus Helotiales sp. Leotiomycene C inhibits the quorum sensing system of methicillin (HY-121544)-resistant Staphylococcus aureus (MRSA), with an IC₅₀ of 6.3-12.5 μM. Leotiomycene C is applicable to research related to MRSA infections .
|
-
| Cat. No. |
Product Name |
Type |
-
- HY-13067G
-
|
Tripterine; Tripterin
|
Fluorescent Dyes
|
|
Celastrol (GMP) (Tripterine (GMP)) is Celastrol (HY-10227) produced by using GMP guidelines. GMP small molecules works appropriately as an auxiliary reagent for cell therapy manufacture. Celastrol (Tripterine;Tripterin) is a proteasome inhibitor which potently and preferentially inhibits the chymotrypsin-like activity of a purified 20S proteasome with IC50 of 2.5 μM. In addition, Celastrol is also an antibiotic with potent antimicrobial activity against standard and clinical methicillin-resistant Staphylococcus aureus (MRSA) strains, inducing oxidative stress and inhibiting DNA synthesis by binding to P5CDH .
|
| Cat. No. |
Product Name |
Type |
-
- HY-W250308A
-
|
Epsilon-polylysine hydrochloride (MV 2000-5000); ε-Polylysine hydrochloride (MV 2000-5000); ε-PL hydrochloride (MV 2000-5000)
|
Biochemical Assay Reagents
|
|
ε-Poly-L-lysine (Epsilon-polylysine; ε-Polylysine) hydrochloride (MV 2000-5000) is a polycationic antibacterial agent with broad-spectrum activity against Gram-positive bacteria, Gram-negative bacteria, fungi, yeasts and specific bacteriophages. ε-Poly-L-lysine hydrochloride (MV 2000-5000) exerts bactericidal effects through mechanisms such as disrupting microbial membranes, inducing ROS production, inhibiting metabolism and spore germination. ε-Poly-L-lysine hydrochloride (MV 2000-5000) also regulates the expression of multiple key genes including sodA, oxyR and recA. ε-Poly-L-lysine hydrochloride (MV 2000-5000) exhibits properties such as low eukaryotic cytotoxicity, thermal stability and pH stability, and supports tissue regeneration and anti-tumor applications. ε-Poly-L-lysine hydrochloride (MV 2000-5000) can be applied in research fields including bacterial and fungal infections, diabetic ulcers, and methicillin-resistant Staphylococcus aureus infections .
|
-
- HY-13067G
-
|
Tripterine; Tripterin
|
Biochemical Assay Reagents
|
|
Celastrol (GMP) (Tripterine (GMP)) is Celastrol (HY-10227) produced by using GMP guidelines. GMP small molecules works appropriately as an auxiliary reagent for cell therapy manufacture. Celastrol (Tripterine;Tripterin) is a proteasome inhibitor which potently and preferentially inhibits the chymotrypsin-like activity of a purified 20S proteasome with IC50 of 2.5 μM. In addition, Celastrol is also an antibiotic with potent antimicrobial activity against standard and clinical methicillin-resistant Staphylococcus aureus (MRSA) strains, inducing oxidative stress and inhibiting DNA synthesis by binding to P5CDH .
|
-
- HY-69174
-
|
|
Biochemical Assay Reagents
|
|
1-Amino-2,5-anhydro-1-deoxy-D-mannitol is a potent antibacterial compound with antibacterial activity against a variety of Gram-positive bacteria, including methicillin-resistant Staphylococcus aureus (MRSA) and vancomycin-resistant Enterococci (VRE). The application potential of 1-Amino-2,5-anhydro-1-deoxy-D-mannitol lies in its ability to effectively combat common drug-resistant bacterial infections. 1-Amino-2,5-anhydro-1-deoxy-D-mannitol may become an emerging antibacterial agent in clinical inhibition.
|
| Cat. No. |
Product Name |
Target |
Research Area |
-
- HY-P10486
-
|
|
Bacterial
|
Infection
|
|
AIP-II is a cyclic peptide signaling molecule for quorum sensing, which is produced by Staphylococcus aureus. AIP-II potently inhibits AgrC-III in Methicillin (HY-121544)-resistant type III Staphylococcus aureus strain AH1747, with an IC50 of 0.532 nM. AIP-II binds to the AgrC-II receptor and regulates virulence gene expression in Staphylococcus aureus .
|
-
- HY-P2460
-
|
|
Bacterial
Fungal
Interleukin Related
TNF Receptor
|
Infection
Inflammation/Immunology
|
|
SMAP‑29 is a cathelicidin antimicrobial peptide with LPS‑binding and anti‑inflammatory properties. SMAP‑29 exerts broad‑spectrum antimicrobial activity against bacteria, fungi and multidrug‑resistant isolates. SMAP‑29 kills pathogens by permeabilizing bacterial membranes, inducing depolarization and cell lysis, and also inhibits inflammatory cytokines while reducing lethality in septic shock and pneumonia models. SMAP-29 can be used for research on bacterial infections, drug-resistant infections, septic shock .
|
-
- HY-P11191
-
|
|
Bacterial
|
Infection
|
|
AR-23 is a melittin-related antimicrobial peptide that can be isolated from Rana tagoi. AR-23 exhibits broad-spectrum growth inhibitory activity against aerobic bacteria, the opportunistic yeast pathogen Candida albicans and clinical isolates of Methicillin (HY-121544)-resistant Staphylococcus aureus (MRSA). AR-23 can be used for antimicrobial research .
|
-
- HY-P11622
-
|
|
Drug Derivative
|
Infection
|
|
Gramicidin S analogue 9 is a bactericidal agent that can be found as a cyclic peptide analogue. Gramicidin S analogue 9 disrupts bacterial cell membranes. Gramicidin S analogue 9 can be used for the research of methicillin-resistant staphylococcus aureus infection .
|
-
- HY-P11607
-
|
|
Bacterial
|
Infection
|
|
CyLip-10 is a microbial-derived cyclic-lipid antimicrobial peptide. CyLip-10 has broad-spectrum antimicrobial efficacy, low hemolytic activity, and excellent stability. CyLip-10 can disrupt membrane integrity, inhibit biofilm formation and induce membrane permeabilization and bacterial cell death. CyLip-10 reduces bacterial load, promotes wound healing, and alleviates inflammatory responses in a mouse Methicillin (HY-121544)-resistant Staphylococcus aureus skin wound infection model. CyLip-10 can be used for the bacterial infection .
|
-
- HY-P11616
-
|
|
Bacterial
TNF Receptor
|
Infection
|
|
WK2 is an antibacterial agent. WK2 reduces serum TNF-α production induced by Bacterial infection. WK2 reduces wound size and promotes tissue repair in a skin wound infection model. WK2 exerts anti-inflammatory effects in a pneumonia model. WK2 can be used for research on infectious diseases such as pneumonia caused by bacterial infection .
|
-
- HY-P11615
-
|
|
Bacterial
|
Infection
|
|
FuK is a WK2-analog antimicrobial peptide modified with fluorinated unnatural amino acids. FuK has an LD50 of 72.34 mg/kg in mice, shows no hemolytic activity, with high stability against trypsin, chymotrypsin, and saline environments. FuK exerts bactericidal effects by enhancing the permeability of bacterial outer membranes, inducing depolarization of cytoplasmic membranes, and disrupting membrane potential balance against bacterias such as Staphylococcus aureus, Escherichia coli, Klebsiella pneumoniae, and MRSA. FuK exhibits synergistic antimicrobial activity with polymyxin B (HY-149179), vancomycin (HY-B0671), and ciprofloxacin (HY-B0356), and also inhibits Ciprofloxacin-induced bacterial drug resistance. FuK has in vivo safety, effectively reduces bacterial load and inflammatory cell infiltration in a mouse MRSA model, and promotes collagen fiber formation in skin wounds .
|
| Cat. No. |
Product Name |
Category |
Target |
Chemical Structure |
-
- HY-13067
-
-
-
- HY-A0097
-
-
-
- HY-A0279
-
-
-
- HY-N10765
-
-
-
- HY-N15451
-
-
-
- HY-156198
-
-
-
- HY-N0241
-
|
|
Flavonols
Structural Classification
Classification of Application Fields
Crassulaceae
Metabolic Disease
Plants
Rhodiola crenulata (HK. f. et.Thoms) H. Ohba
Flavonoids
Rhodiola rosea Linn.
Phenols
Polyphenols
Disease Research Fields
Source Classification
|
Cholinesterase (ChE)
Lipase
Bacterial
Cytochrome P450
|
|
Rhodionin is an orally active, multifunctional antivirulence and cytoprotective agent that targets and inhibits Lipase, sortase A (SrtA), CYP2D6 (IC50=0.761 μM), AChE (IC50=2.43-57.5 μM), and DPPH free radicals (IC50=19.49 μM). Rhodionin is isolable from the roots of Rhodiola crenulata. Rhodionin reduces postprandial serum triglyceride levels in mice by inhibiting lipase activity. Rhodionin also binds directly to SrtA to inhibit its transpeptidase activity, thereby reducing the fibrinogen adhesion and surface protein A levels of MRSA, effectively inhibiting biofilm formation and protecting against MRSA-induced cell damage. Rhodionin improves the survival rate of infected mice without affecting MRSA growth, and finds wide application in studies related to hyperlipidemia, exogenous obesity, and pneumonia induced by methicillin-resistant Staphylococcus aureus (MRSA) .
|
-
-
- HY-127072
-
|
|
Structural Classification
Microorganisms
Antibiotics
Other Antibiotics
Source Classification
|
Antibiotic
Bacterial
|
|
Amicoumacin A is an orally active antibiotic. Amicoumacin A targets bacterial ribosomes and inhibits bacterial translation by stabilizing the interaction between mRNA and ribosomes. Amicoumacin A induces cancer cell death by targeting eukaryotic ribosomes. Amicoumacin A exhibits anti-inflammatory and anti-ulcer activities, inhibits carrageenan-induced paw edema, and prevents stress-induced gastric ulcers. Amicoumacin A inhibits the growth of Gram-positive bacteria, Salmonella spp., Shigella spp., Helicobacter pylori, and methicillin-resistant Staphylococcus aureus. Amicoumacin A can be used in the research of lung cancer, breast cancer, bacterial infections, inflammatory edema and gastric ulcers [2] .
|
-
-
- HY-142124
-
-
-
- HY-127155
-
-
-
- HY-W060074
-
-
-
- HY-N10834
-
|
|
Natural Products
Plants
Compositae
Source Classification
Erythrina sigmoidea Hua
|
Bacterial
|
|
(6E,12E)-Tetradecadiene-8,10-diyne-1,3-diol is an antibacterial compound. (6E,12E)-Tetradecadiene-8,10-diyne-1,3-diol can be isolated from the roots of Atractylodes japonica. (6E,12E)-Tetradecadiene-8,10-diyne-1,3-diol has anti-methicillin-resistant Staphylococcus aureus (MRSA) activity with MIC values of 4-32 μg/mL. (6E,12E)-Tetradecadiene-8,10-diyne-1,3-diol can be used for the research of bacterial infection . (6E,12E)-Tetradecadiene-8,10-diyne-1,3-diol is a click chemistry reagent, it contains an Alkyne group and can undergo copper-catalyzed azide-alkyne cycloaddition (CuAAc) with molecules containing Azide groups.
|
-
-
- HY-N7010
-
-
-
- HY-124199
-
|
|
Microorganisms
Antibiotics
Other Antibiotics
Source Classification
|
Antibiotic
Bacterial
|
|
Cephalochromin is an antibiotic and an inhibitor for bacterial fatty acid synthase (FabI). Cephalochromin inhibits FabI of Staphylococcus aureus and Escherichia coli with IC50 of 1.9 and 1.8 μM. Cephalochromin inhibits gram-positive methicillin-resistant S. aureus (MRSA) and quinolone-resistant S. aureus (QRSA), with MIC of 2-8 µg/mL .
|
-
-
- HY-N16403
-
|
|
Structural Classification
Natural Products
Microorganisms
Source Classification
|
Cytochrome P450
Endogenous Metabolite
Bacterial
Insecticide
Fungal
|
|
Aspergillusidone F is a Depsidone and antibacterial agent. Aspergillusidone F can be isolated from a marine fungus Aspergillus unguis. Aspergillusidone F potently inhibits Aromatase with an IC50 of 0.5 μM. Aspergillusidone F exhibits antibacterial activity against Pseudomonas aeruginosa and Methicillin (HY-121544)-resistant Staphylococcus aureus. Aspergillusidone F exhibits potent larvicidal activity against Artemia salina larvae, with an LC50 value of 12.8 μM. Aspergillusidone F exhibits anticancer activity against intrahepatic cholangiocarcinoma, non-small cell lung cancer, and acute lymphoblastic leukemia .
|
-
-
- HY-A0097A
-
|
Antibiotic MDL-507 sodium; MDL-507 sodium
|
Phenols
Polyphenols
Endogenous metabolite
Source Classification
|
Antibiotic
HIV
SARS-CoV
|
|
Teicoplanin sodium is a glycopeptide antibiotic indicated for use in serious infections caused by Gram-positive bacteria, including Methicillin-resistant Staphylococcus aureus and Enterococcus aureus.Teicoplanin sodium shows antiviral activity for HIV-1, SARS-CoV1 and SARS-CoV2. Teicoplanin sodium shows anti-MRSA activity .
|
-
-
- HY-135422
-
|
Methylustin
|
Natural Products
Microorganisms
Source Classification
|
Bacterial
Fungal
|
|
Nidulin (Methylustin) is a depsidone isolated from a marine fungus Aspergillus unguis. Nidulin shows antifungal and antibacterial against pathogenetic strains, Pseudomonas aeruginosa, Methicillin-resistant Staphylococcus aureus and Candida albicans with inhibition zones of 9.5 mm, 9.0 mm and 9.0 mm, respectively. Nidulin exhibits potent larvicidality against brine shrimp .
|
-
-
- HY-N15272
-
-
-
- HY-N3789
-
-
-
- HY-N3989
-
-
-
- HY-N15435
-
|
|
Apocynaceae
Structural Classification
Alkaloids
Other Alkaloids
Plants
Holarrhena antidysenterica Roth
Source Classification
|
Bacterial
|
|
Conimine is a steroidal alkaloid, antibacterial agent and potentiator. Conimine is isolated from the seeds of Holarrhena antidysenteriaca Wall.ex A.DC. Conimine exhibits intrinsic antibacterial activity against methicillin-sensitive Staphylococcus aureus and methicillin-resistant Staphylococcus aureus. When combined with Penicillin, Conimine shows synergistic antibacterial effects against methicillin-resistant Staphylococcus aureus; when combined with Vancomycin (HY-B0671), it exerts synergistic antibacterial effects against both methicillin-sensitive and methicillin-resistant Staphylococcus aureus .
|
-
-
- HY-N14125
-
-
-
- HY-N8186
-
-
-
- HY-N13885
-
-
-
- HY-N14118
-
-
-
- HY-N14673
-
-
-
- HY-N13881
-
-
-
- HY-N14470
-
-
-
- HY-N14476
-
-
-
- HY-N14675
-
-
-
- HY-N14706
-
-
-
- HY-N14707
-
-
-
- HY-N14710
-
-
-
- HY-116168
-
-
-
- HY-N14709
-
-
-
- HY-N14708
-
-
-
- HY-N5195
-
-
-
- HY-N5184
-
-
-
- HY-N14899
-
-
-
- HY-N14955
-
-
-
- HY-N15019
-
-
-
- HY-N14171
-
-
-
- HY-N19935
-
-
-
- HY-N14144
-
-
-
- HY-121000
-
-
-
- HY-N11879
-
-
-
- HY-N10907
-
-
-
- HY-161935
-
|
|
Lysimachia tengyuehensis Hand.-Mazz.
Antibiotics
Plants
Primulaceae
Other Antibiotics
Source Classification
|
Bacterial
|
|
6-(12-Tridecene-1-yl)-2,4-Dihydroxy benzoic acid (Compound 2) exhibits antibacterial activity against methicillin-resistant Staphylococcus aureus (MRSA) and Vancomycin enterococci (VRE). 6-(12-Tridecene-1-yl)-2,4-Dihydroxy benzoic acid interfers with the integrity and function of the bacterial cell membrane, and affects metabolism in MRSA. 6-(12-Tridecene-1-yl)-2,4-Dihydroxy benzoic acid exhibits anti-inflammatory and anti-infective efficacy, and promotes angiogenesis in mice .
|
-
-
- HY-N10561
-
|
|
Microorganisms
Antibiotics
Antibacterial
Disease Research
|
Bacterial
|
|
Wychimicin A is a spirotetronate polyketide, can be isolated from the rare actinomycete Actinocrispum wychmicini strain MI503-AF4. Wychimicin A shows strong antibacterial activity against methicillin-resistant Staphylococcus. aureus (IC50=0.125-0.5 μg/mL) and Enterococcus. faecalis/faecium (IC50=0.125-0.25 μg/mL) .
|
-
-
- HY-N10560
-
|
|
Microorganisms
Antibiotics
Antibacterial
Disease Research
|
Bacterial
|
|
Wychimicin C is a spirotetronate polyketide, can be isolated from the rare actinomycete Actinocrispum wychmicini strain MI503-AF4. Wychimicin C shows strong antibacterial activity against methicillin-resistant Staphylococcus. aureus (IC50=0.125-0.5 μg/mL) and Enterococcus. faecalis/faecium (IC50=0.125-0.25 μg/mL) .
|
-
- HY-N15249
-
|
Isovalerylspiramycin I; Shengjimycin E
|
Structural Classification
Natural Products
Microorganisms
Source Classification
|
Topoisomerase
DNA/RNA Synthesis
Checkpoint Kinase (Chk)
Apoptosis
Bacterial
|
|
4"-Isovalerylspiramycin I (Isovalerylspiramycin I) is a topoisomerase 1 (TOP1) inhibitor and an antitumor agent. 4"-Isovalerylspiramycin I directly binds to TOP1, suppresses DNA replication, and induces DNA damage. 4"-Isovalerylspiramycin I downregulates phosphorylated CHEK1 and the ATR/CHEK1 DNA damage repair pathway, blocks DNA repair, and augments DNA damage. 4"-Isovalerylspiramycin I suppresses proliferation, migration, and invasion of osteosarcoma cells. 4"-Isovalerylspiramycin I induces apoptosis and cell cycle arrest in osteosarcoma cells. 4"-Isovalerylspiramycin I exerts antibacterial activity against methicillin-resistant Staphylococcus aureus. 4"-Isovalerylspiramycin I can be used for the research of osteosarcoma, upper respiratory bacterial infections, and methicillin-resistant Staphylococcus aureus infection .
|
-
- HY-N14119
-
-
- HY-18704
-
|
(+)-Cyslabdan
|
Natural Products
Microorganisms
Source Classification
|
Others
|
|
Cyslabdan ((+)-Cyslabdan) is a novel compound with the potential to enhance the activity of imipenem against methicillin-resistant Staphylococcus aureus. Cyslabdan exerts its antibacterial effect by inhibiting the synthesis of pentapeptide cross-links .
|
-
- HY-N5196
-
-
- HY-N15755
-
-
- HY-N16526
-
-
- HY-N9833
-
-
- HY-N14145
-
-
- HY-N14172
-
-
- HY-N9819
-
-
- HY-N14530
-
|
|
Natural Products
Microorganisms
Source Classification
|
Bacterial
|
|
Cremeomycin has anti-Gram-positive bacteria activity including methicillin-resistant Staphylococcus aureus (MRSA), MIC is 0.2-0.39 μg/mL. Cremeomycin shows cytotoxicity to mouse tumor cell lines P388, L1210, IMC, S180, B16 and SS3 in vitro .
|
-
- HY-N14484
-
|
|
Natural Products
Microorganisms
Source Classification
|
Bacterial
|
|
Kigamicin D shows activity against Gram-positive bacteria including methicillin-resistant Staphylococcus aureus (MRSA) with MICs of 0.025-0.78 μg/mL. Kigamicin D also shows effect against L-1210 LB32T and other genera tumor cells with IC50 of 1 μg/mL .
|
-
- HY-N19293
-
-
- HY-N19290
-
-
- HY-130052
-
-
- HY-N18102
-
|
|
Structural Classification
Commiphora myrrha (Nees) Engl.
Ketones, Aldehydes, Acids
Plants
Burseraceae
Source Classification
|
Bacterial
|
|
3,4-Seco-mansumbinoic acid (Compound 2) is an Antibacterial agent. 3,4-Seco-mansumbinoic acid can be isolated from the oleo-resin of Commiphora molmol. 3,4-Seco-mansumbinoic acid exhibits in vitro anti-staphylococcal activity, with the strongest activity against the multidrug-resistant Staphylococcus aureus strain SA-1199B (MIC 4 μg/mL) 3,4-Seco-mansumbinoic acid displays weak potentiation of Ciprofloxacin (HY-B0356) and Tetracycline (HY-A0107) activity against strains of Salmonella enterica serovar Typhimurium SL1344 and L10. 3,4-Seco-mansumbinoic acid can be used for the research of multidrug-resistant bacterial infection (Staphylococcus aureus, Salmonella enterica serovar Typhimurium) .
|
-
- HY-N19220
-
|
|
Structural Classification
Microorganisms
Lipid
Source Classification
|
Bacterial
Endogenous Metabolite
Antibiotic
|
|
Radiclonic acid acts as an antibacterial agent, anticancer agent, and root growth promoter. Radiclonic acid is isolable from fungi of the genus Penicillium. Radiclonic acid exhibits antibacterial activity against MRSA with a MIC of 3.13 μg/mL. Radiclonic acid shows anticancer activity against esophageal cancer, bladder cancer, and liver cancer. Radiclonic acid promotes root growth in Chinese cabbage seedlings. Radiclonic acid is inactive against pancreatic cancer and cervical cancer. Radiclonic acid can be used in research related to Staphylococcus aureus infection, bladder cancer, esophageal cancer, and liver cancer .
|
-
- HY-W142206
-
-
- HY-N17297
-
-
| Cat. No. |
Product Name |
|
Classification |
-
- HY-174333
-
|
|
|
Alkynes
|
|
CYP1A1-IN-1 (Compound 47) is a small-molecule cytochrome P4501A1 (CYP1A1) inhibitor. CYP1A1-IN-1 reduces the bacterial loads of methicillin-resistant Staphylococcus aureus (MRSA) and Acinetobacter baumannii by enhancing macrophage phagocytosis. CYP1A1-IN-1 is promising for research of sepsis caused by multidrug-resistant (MDR) bacteria .
|
-
- HY-N16526
-
|
|
|
Alkynes
|
|
Juncatrin B is a type of dihydrophenanthrene compound. Juncatrin B exhibits inhibitory activity against both Methicillin (HY-121544)-sensitive Staphylococcus aureus (MSSA) and Methicillin-resistant Staphylococcus aureus (MRSA). Juncatrin B can inhibit the formation of biofilms in MSSA and MRSA. Juncatrin B has no significant activity against Gram-negative bacteria. Juncatrin B can be used in the research of anti-Staphylococcus aureus .
|
| Cat. No. |
Product Name |
Target |
Research Areas |
Chemical Structure |
-
- HY-13067G
-
|
Tripterine; Tripterin
|
Endogenous Metabolite
Proteasome
Antibiotic
Apoptosis
Bacterial
Autophagy
Mitophagy
|
Infection
Inflammation/Immunology
Cancer
|
|
Celastrol (GMP) (Tripterine (GMP)) is Celastrol (HY-10227) produced by using GMP guidelines. GMP small molecules works appropriately as an auxiliary reagent for cell therapy manufacture. Celastrol (Tripterine;Tripterin) is a proteasome inhibitor which potently and preferentially inhibits the chymotrypsin-like activity of a purified 20S proteasome with IC50 of 2.5 μM. In addition, Celastrol is also an antibiotic with potent antimicrobial activity against standard and clinical methicillin-resistant Staphylococcus aureus (MRSA) strains, inducing oxidative stress and inhibiting DNA synthesis by binding to P5CDH .
|
-
Your information is safe with us. * Required Fields.
Inquiry Information
- Product Name:
- Cat. No.:
- Quantity:
- MCE Japan Authorized Agent: